Download PDF

Clinical Trial Results:
A phase II, randomized, controlled, observer-blind study to evaluate the impact of two formulations of GlaxoSmithKline (GSK) Biologicals’ combined 10-valent pneumococcal polysaccharide and non-typeable Haemophilus influenzae protein D conjugate and pneumococcal protein vaccine on nasopharyngeal carriage, safety and immunogenicity when co-administered with routine EPI vaccines in infants following safety assessment in children aged 2-4 years in the Gambia.

Summary
EudraCT number	2012-002727-15
Trial protocol	Outside EU/EEA
Global end of trial date	18 Mar 2013

Results information
Results version number	v2
This version publication date	02 Jul 2016
First version publication date	26 Jul 2015
Other versions	v1 , v3 , v4
Version creation reason	New data added to full data set Data for primary/secondary endpoints have been added.

Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information

Collapse all Expand all

Trial information

Top of page

Sponsor protocol code

114174

ISRCTN number

US NCT number

NCT01262872

WHO universal trial number (UTN)

Sponsor organisation name

GlaxoSmithKline Biologicals

Sponsor organisation address

Rue de l’Institut 89, Rixensart, Belgium, B-1330

Public contact

Clinical Trials Call Center, GlaxoSmithKline Biologicals, 44 2089904466, GSKClinicalSupportHD@gsk.com

Scientific contact

Clinical Trials Call Center, GlaxoSmithKline Biologicals, 44 2089904466, GSKClinicalSupportHD@gsk.com

Is trial part of an agreed paediatric investigation plan (PIP)

Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?

Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?

Yes

Analysis stage

Interim

Date of interim/final analysis

06 Apr 2016

Is this the analysis of the primary completion data?

Global end of trial reached?

Yes

Global end of trial date

18 Mar 2013

Was the trial ended prematurely?

Main objective of the trial

- To assess the safety and reactogenicity of GSK Biologicals’ combined Synflorix™(10Pn-PD-DiT) and pneumococcal protein vaccine when administered (high dose formulation [HD]) as a one-dose schedule to children aged 2-4 years, in terms of occurrence of grade 3 related solicited and unsolicited adverse events and related serious adverse events. (Cohort 1, young children) -To assess the impact of GSK Biologicals’ combined Synflorix™(10Pn-PD-DiT) and pneumococcal protein vaccine on nasopharyngeal carriage of non-vaccine S. pneumoniae serotypes when co-administered with routine EPI vaccines as a 3-dose vaccination course (either at 2-3-4 months of age for the low dose (LD) and high dose (HD) formulations or at 2-4-9 months of age for the HD formulation). (Cohort 2, infants) Note: Routine EPI paediatric immunization in The Gambia includes vaccination against diphtheria, tetanus, pertussis, measles and yellow fever.

Protection of trial subjects

GSK monitored the study to verify that, amongst others, the data were authentic, accurate, and complete; Safety and rights of subjects were being protected; Study was conducted in accordance with the currently approved protocol and any amendments, any other study agreements, GCP and all applicable regulatory requirements. The investigator and the head of the medical institution (where applicable) agreed to allow the monitor direct access to all relevant documents. All subjects were supervised closely for at least 30 minutes following vaccination with appropriate medical treatment readily available. Vaccines were administered by qualified and trained personnel. Vaccines were administered only to eligible subjects that had no contraindications to any components of the vaccines. Subjects were followed-up from the time the subject consents to participate in the study until she/he was discharged.

Background therapy

Evidence for comparator

Actual start date of recruitment

09 Feb 2011

Long term follow-up planned

Independent data monitoring committee (IDMC) involvement?

Yes

Number of subjects enrolled per country

Country: Number of subjects enrolled

Gambia: 1320

Worldwide total number of subjects

1320

EEA total number of subjects

Number of subjects enrolled per age group

In utero

Preterm newborn - gestational age < 37 wk

Newborns (0-27 days)

Infants and toddlers (28 days-23 months)

1200

Children (2-11 years)

120

Adolescents (12-17 years)

Adults (18-64 years)

From 65 to 84 years

85 years and over

Subject disposition

Top of page

Recruitment details

Cohort 1 subjects participated in Step 1 (duration of about 6 months). Cohort 2 subjects participated in Step 2 (duration of about 10 months). Enrolment for Step 2 was conditional upon successful results of a post-vaccination safety evaluation of all children enrolled in Cohort 1 by an Independent Data Monitoring Committee.

Screening details

During the screening the following steps occurred: check for inclusion/exclusion criteria, contraindications/precautions, medical history of the subjects and signing informed consent forms.

Period 1 title

Overall Study (overall period)

Is this the baseline period?

Yes

Allocation method

Randomised - controlled

Blinding used

Double blind

Roles blinded

Subject, Investigator, Monitor, Carer, Assessor

Blinding implementation details

Step 1 of the study was conducted in an observer-blind manner. Step 2 was conducted in an observed-blind manner inside each defined vaccination schedule and open between schedules. By observer-blind, it is meant that during the course of the study, the vaccine recipient and those responsible for the evaluation of any study endpoint (e.g., carriage, safety, reactogenicity and immunogenicity) were all unaware of which vaccine was administered.

Are arms mutually exclusive

Yes

10PP-LD 3+0d Group

Arm description

This group consisted in infants aged 8-10 weeks at first vaccination enrolled as part the Cohort 2/Step 2 of the study who received 3 doses of the GSK 2189242A (or 10PP) vaccine in its low-dose (LD) formulation and EPI vaccines according to a 3+0 Schedule. That is, subjects received 3 doses of the 10PP vaccine, LD formulation, co-administered with Tritanrix™-HepB/Hib and Polio Sabin™ at 2-3-4 months of age (Day 0, Month 1 and Month 2), followed by one dose of each of the M-Vac™, Stamaril™ and Polio Sabin™ vaccines administered at approximately 9 months of age. The 10PP vaccine was administered intramuscularly into the right thigh; Tritanrix™-HepB/Hib, M-Vac™ and Stamaril™ were administered intramuscularly into the left thigh; Polio Sabin™ was administered orally.

Arm type

Experimental

Investigational medicinal product name

Pneumococcal vaccine GSK 2189242A (LD formulation 1)

Investigational medicinal product code

Other name

10PP, LD Formulation

Pharmaceutical forms

Suspension for injection

Routes of administration

Intramuscular use

Dosage and administration details

Intramuscular injection (IM) into the right thigh.

Investigational medicinal product name

Tritanrix™-HepB/Hib

Investigational medicinal product code

Other name

DTPw-HBV/Hib

Pharmaceutical forms

Suspension for injection

Routes of administration

Intramuscular use

Dosage and administration details

Intramuscular injection (IM)administered into the left thigh.

Investigational medicinal product name

Polio Sabin™

Investigational medicinal product code

Other name

Oral Polio vaccine (OPV)

Pharmaceutical forms

Oral suspension

Routes of administration

Oral use

Dosage and administration details

The vaccine was administered orally.

Investigational medicinal product name

M-Vac™

Investigational medicinal product code

Other name

Measles

Pharmaceutical forms

Powder and suspension for suspension for injection

Routes of administration

Intramuscular use

Dosage and administration details

The vaccine was administered into the left thigh.

Investigational medicinal product name

Stamaril™

Investigational medicinal product code

Other name

Yellow Fever Vaccine (YFV)

Pharmaceutical forms

Powder and solvent for suspension for injection

Routes of administration

Intramuscular use

Dosage and administration details

The vaccine was administered into the left thigh.

10PP-HD 3+0d Group

Arm description

This group consisted in infants aged 8-10 weeks at first vaccination enrolled as part the Cohort 2/Step 2 of the study who received 3 doses of the GSK 2189242A (or 10PP) vaccine in its high-dose (HD) formulation and EPI vaccines according to a 3+0 Schedule. That is, subjects received 3 doses of the 10PP vaccine, HD formulation, co-administered with the Tritanrix™-HepB/Hib and Polio Sabin™ at 2-3-4 months of age (Day 0, Month 1 and Month 2), followed by one dose of each of the M-Vac™, Stamaril™ and Polio Sabin™ vaccines administered at approximately 9 months of age. The 10PP vaccine was administered intramuscularly into the right thigh; Tritanrix™-HepB/Hib, M-Vac™ and Stamaril™ were administered intramuscularly into the left thigh; Polio Sabin™ was administered orally.

Arm type

Experimental

Investigational medicinal product name

Pneumococcal vaccine GSK 2189242A (HD formulation 2)

Investigational medicinal product code

Other name

10PP, HD Formulation

Pharmaceutical forms

Suspension for injection

Routes of administration

Intramuscular use

Dosage and administration details

Intramuscular injection (IM) into the right thigh.

Investigational medicinal product name

Tritanrix™-HepB/Hib

Investigational medicinal product code

Other name

DTPw-HBV/Hib

Pharmaceutical forms

Suspension for injection

Routes of administration

Intramuscular use

Dosage and administration details

The vaccine was administered into the left thigh.

Investigational medicinal product name

Polio Sabin™

Investigational medicinal product code

Other name

Oral Polio vaccine (OPV)

Pharmaceutical forms

Oral suspension

Routes of administration

Oral use

Dosage and administration details

The vaccine was administered orally.

Investigational medicinal product name

M-Vac™

Investigational medicinal product code

Other name

Measles

Pharmaceutical forms

Powder and suspension for suspension for injection

Routes of administration

Intramuscular use

Dosage and administration details

The vaccine was administered into the left thigh.

Investigational medicinal product name

Stamaril™

Investigational medicinal product code

Other name

Yellow Fever Vaccine (YFV)

Pharmaceutical forms

Powder and solvent for suspension for injection

Routes of administration

Intramuscular use

Dosage and administration details

The vaccine was administered into the left thigh.

Synflorix 3+0d Group

Arm description

This group consisted in infants aged 8-10 weeks at first vaccination enrolled as part the Cohort 2/Step 2 of the study who received 3 doses of Synflorix™ and EPI vaccines according to a 3+0 Schedule. That is, subjects received 3 doses of the Synflorix™, co-administered with Tritanrix™-HepB/Hib and Polio Sabin™ at 2-3-4 months of age (Day 0, Month 1 and Month 2), followed by one dose of each of the M-Vac™, Stamaril™ and Polio Sabin™ vaccines administered at approximately 9 months of age. Synflorix™ was administered intramuscularly into the right thigh; Tritanrix™-HepB/Hib, M-Vac™ and Stamaril™ were administered intramuscularly into the left thigh; Polio Sabin™ was administered orally.

Arm type

Active comparator

Investigational medicinal product name

Synflorix™

Investigational medicinal product code

Other name

10Pn-PD-DiT vaccine

Pharmaceutical forms

Suspension for injection

Routes of administration

Intramuscular use

Dosage and administration details

Intramuscular injection (IM) into the right thigh.

Investigational medicinal product name

Tritanrix™-HepB/Hib

Investigational medicinal product code

Other name

DTPw-HBV/Hib

Pharmaceutical forms

Suspension for injection

Routes of administration

Intramuscular use

Dosage and administration details

The vaccine was administered into the left thigh.

Investigational medicinal product name

Polio Sabin™

Investigational medicinal product code

Other name

Oral Polio vaccine (OPV)

Pharmaceutical forms

Oral suspension

Routes of administration

Oral use

Dosage and administration details

The vaccine was administered orally.

Investigational medicinal product name

M-Vac™

Investigational medicinal product code

Other name

Measles

Pharmaceutical forms

Powder and suspension for suspension for injection

Routes of administration

Intramuscular use

Dosage and administration details

The vaccine was administered into the left thigh.

Investigational medicinal product name

Stamaril™

Investigational medicinal product code

Other name

Yellow Fever Vaccine (YFV)

Pharmaceutical forms

Powder and solvent for suspension for injection

Routes of administration

Intramuscular use

Dosage and administration details

The vaccine was administered into the left thigh.

Prevnar13 3+0d Group

Arm description

This group consisted in infants aged 8-10 weeks at first vaccination enrolled as part the Cohort 2/Step 2 of the study who received 3 doses of Prevnar 13™ and EPI vaccines according to a 3+0 Schedule. That is, subjects received 3 doses of Prevnar 13™, co-administered with Tritanrix™-HepB/Hib and Polio Sabin™ at 2-3-4 months of age (Day 0, Month 1 and Month 2), followed by one dose of each of the M-Vac™, Stamaril™ and Polio Sabin™ vaccines administered at approximately 9 months of age. Prevnar 13™ was administered intramuscularly into the right thigh; Tritanrix™-HepB/Hib, M-Vac™ and Stamaril™ were administered intramuscularly into the left thigh; Polio Sabin™ was administered orally.

Arm type

Active comparator

Investigational medicinal product name

Prevnar13™

Investigational medicinal product code

Other name

Prev13

Pharmaceutical forms

Suspension for injection

Routes of administration

Intramuscular use

Dosage and administration details

Intramuscular injection (IM) into the right thigh.

Investigational medicinal product name

Tritanrix™-HepB/Hib

Investigational medicinal product code

Other name

DTPw-HBV/Hib

Pharmaceutical forms

Suspension for injection

Routes of administration

Intramuscular use

Dosage and administration details

The vaccine was administered into the left thigh.

Investigational medicinal product name

Polio Sabin™

Investigational medicinal product code

Other name

Oral Polio vaccine (OPV)

Pharmaceutical forms

Oral suspension

Routes of administration

Oral use

Dosage and administration details

The vaccine was administered orally.

Investigational medicinal product name

M-Vac™

Investigational medicinal product code

Other name

Measles

Pharmaceutical forms

Powder and suspension for suspension for injection

Routes of administration

Intramuscular use

Dosage and administration details

The vaccine was administered into the left thigh.

Investigational medicinal product name

Stamaril™

Investigational medicinal product code

Other name

Yellow Fever Vaccine (YFV)

Pharmaceutical forms

Powder and solvent for suspension for injection

Routes of administration

Intramuscular use

Dosage and administration details

The vaccine was administered into the left thigh.

10PP-HD 2+1d Group

Arm description

This group consisted in infants aged 8-10 weeks at first vaccination enrolled as part the Cohort 2/Step 2 of the study who received the GSK 2189242A (or 10PP) vaccine, in its high-dose (HD) formulation, and EPI vaccines according to a 2+1 Schedule. That is, subjects received 2 doses of the 10PP vaccine, HD formulation co-administered with Tritanrix™-Hep B/Hib and Polio Sabin™ at 2-4 months of age (at Day 0 and Month 2), followed by a third dose of the same formulation co-administered with M-Vac™, Stamaril™ and Polio Sabin™ at approximately 9 months of age.. The 2nd doses of Tritanrix™-Hep B/Hib and Polio Sabin™ in EPI vaccines were administered without any pneumococcal vaccine at 3 months of age. The 10PP vaccine was administered intramuscularly into the right thigh; Tritanrix™-HepB/Hib, M-Vac™ and Stamaril™ were administered intramuscularly into the left thigh; Polio Sabin™ was administered orally.

Arm type

Experimental

Investigational medicinal product name

Pneumococcal vaccine GSK 2189242A (HD formulation 2)

Investigational medicinal product code

Other name

10PP, HD Formulation

Pharmaceutical forms

Suspension for injection

Routes of administration

Intramuscular use

Dosage and administration details

Intramuscular injection (IM) into the right thigh.

Investigational medicinal product name

Tritanrix™-HepB/Hib

Investigational medicinal product code

Other name

DTPw-HBV/Hib

Pharmaceutical forms

Suspension for injection

Routes of administration

Intramuscular use

Dosage and administration details

The vaccine was administered into the left thigh.

Investigational medicinal product name

Polio Sabin™

Investigational medicinal product code

Other name

Oral Polio vaccine (OPV)

Pharmaceutical forms

Oral suspension

Routes of administration

Oral use

Dosage and administration details

The vaccine was administered orally.

Investigational medicinal product name

M-Vac™

Investigational medicinal product code

Other name

Measles

Pharmaceutical forms

Powder and suspension for suspension for injection

Routes of administration

Intramuscular use

Dosage and administration details

The vaccine was administered into the left thigh.

Investigational medicinal product name

Stamaril™

Investigational medicinal product code

Other name

Yellow Fever Vaccine (YFV)

Pharmaceutical forms

Powder and solvent for suspension for injection

Routes of administration

Intramuscular use

Dosage and administration details

The vaccine was administered into the left thigh.

Synflorix 2+1d Group

Arm description

This group consisted in infants aged 8-10 weeks at first vaccination enrolled as part the Cohort 2/Step 2 of the study who received Synflorix™ and EPI vaccines according to a 2+1 Schedule. That is, subjects received 2 doses of the Synflorix™ co-administered with Tritanrix™-Hep B/Hib and Polio Sabin™ at 2-4 months of age (at Day 0 and Month 2), followed by a third dose of Synflorix™ co-administered with M-Vac™, Stamaril™ and Polio Sabin™ at approximately 9 months of age. The 2nd doses of Tritanrix™-Hep B/Hib and Polio Sabin™ in EPI vaccines were administered without any pneumococcal vaccine at 3 months of age. Synflorix™ was administered intramuscularly into the right thigh; Tritanrix™-HepB/Hib, M-Vac™ and Stamaril™ were administered intramuscularly into the left thigh; Polio Sabin™ was administered orally.

Arm type

Active comparator

Investigational medicinal product name

Synflorix™

Investigational medicinal product code

Other name

10Pn-PD-DiT vaccine

Pharmaceutical forms

Suspension for injection

Routes of administration

Intramuscular use

Dosage and administration details

Intramuscular injection (IM) into the right thigh.

Investigational medicinal product name

Tritanrix™-HepB/Hib

Investigational medicinal product code

Other name

DTPw-HBV/Hib

Pharmaceutical forms

Suspension for injection

Routes of administration

Intramuscular use

Dosage and administration details

The vaccine was administered into the left thigh.

Investigational medicinal product name

Polio Sabin™

Investigational medicinal product code

Other name

Oral Polio vaccine (OPV)

Pharmaceutical forms

Oral suspension

Routes of administration

Oral use

Dosage and administration details

The vaccine was administered orally.

Investigational medicinal product name

M-Vac™

Investigational medicinal product code

Other name

Measles

Pharmaceutical forms

Powder and suspension for suspension for injection

Routes of administration

Intramuscular use

Dosage and administration details

The vaccine was administered into the left thigh.

Investigational medicinal product name

Stamaril™

Investigational medicinal product code

Other name

Yellow Fever Vaccine (YFV)

Pharmaceutical forms

Powder and solvent for suspension for injection

Routes of administration

Intramuscular use

Dosage and administration details

The vaccine was administered into the left thigh.

10PP-HD 1d Group

Arm description

This group consisted in children aged 2-4 years at vaccination enrolled as part of the Cohort 1/Step 1 of the study who received a single dose of the GSK 2189242A (or 10PP) vaccine in its high-dose (HD) formulation at Day 0. The 10PP vaccine was administered intramuscularly in the non-dominant deltoid.

Arm type

Experimental

Investigational medicinal product name

Pneumococcal vaccine GSK 2189242A (LD formulation 1)

Investigational medicinal product code

Other name

10PP, LD Formulation

Pharmaceutical forms

Suspension for injection

Routes of administration

Intramuscular use

Dosage and administration details

Intramuscular injection (IM) into the deltoid region of the non-dominant arm.

Prevnar13 1d Group

Arm description

This group consisted in children aged 2-4 years at vaccination enrolled as part of the Cohort 1/Step 1 of the study who received a single dose of Prevnar 13™ at Day 0. Prevnar 13™ was administered intramuscularly in the non-dominant deltoid.

Arm type

Active comparator

Investigational medicinal product name

Prevnar13™

Investigational medicinal product code

Other name

Prev13

Pharmaceutical forms

Suspension for injection

Routes of administration

Intramuscular use

Dosage and administration details

Intramuscular injection (IM) into the deltoid region of the non-dominant arm.

Number of subjects in period 1	10PP-LD 3+0d Group	10PP-HD 3+0d Group	Synflorix 3+0d Group	Prevnar13 3+0d Group	10PP-HD 2+1d Group	Synflorix 2+1d Group	10PP-HD 1d Group	Prevnar13 1d Group
Started	200	200	200	200	200	200	60	60
Completed	191	190	195	191	191	194	60	60
Not completed	9	10	5	9	9	6	0	0
Adverse event, serious fatal	-	1	-	2	2	1	-	-
Consent withdrawn by subject	4	6	3	1	2	1	-	-
Migrated/moved from study area	4	3	2	6	2	3	-	-
Protocol deviation	1	-	-	-	3	1	-	-

Baseline characteristics

Top of page

Reporting group title

10PP-LD 3+0d Group

Reporting group description

Reporting group title

10PP-HD 3+0d Group

Reporting group description

This group consisted in infants aged 8-10 weeks at first vaccination enrolled as part the Cohort 2/Step 2 of the study who received 3 doses of the GSK 2189242A (or 10PP) vaccine in its high-dose (HD) formulation and EPI vaccines according to a 3+0 Schedule. That is, subjects received 3 doses of the 10PP vaccine, HD formulation, co-administered with the Tritanrix™-HepB/Hib and Polio Sabin™ at 2-3-4 months of age (Day 0, Month 1 and Month 2), followed by one dose of each of the M-Vac™, Stamaril™ and Polio Sabin™ vaccines administered at approximately 9 months of age. The 10PP vaccine was administered intramuscularly into the right thigh; Tritanrix™-HepB/Hib, M-Vac™ and Stamaril™ were administered intramuscularly into the left thigh; Polio Sabin™ was administered orally.

Reporting group title

Synflorix 3+0d Group

Reporting group description

Reporting group title

Prevnar13 3+0d Group

Reporting group description

Reporting group title

10PP-HD 2+1d Group

Reporting group description

Reporting group title

Synflorix 2+1d Group

Reporting group description

Reporting group title

10PP-HD 1d Group

Reporting group description

Reporting group title

Prevnar13 1d Group

Reporting group description

Reporting group values	10PP-LD 3+0d Group	10PP-HD 3+0d Group	Synflorix 3+0d Group	Prevnar13 3+0d Group	10PP-HD 2+1d Group	Synflorix 2+1d Group	10PP-HD 1d Group	Prevnar13 1d Group	Total
Number of subjects	200	200	200	200	200	200	60	60	1320
Age categorical
Units: Subjects
Infants and toddlers (28 days-23 months)	200	200	200	200	200	200	0	0	1200
Children (2-11 years)	0	0	0	0	0	0	60	60	120
Gender categorical
Units: Subjects
Female	105	98	103	103	103	97	41	26	676
Male	95	102	97	97	97	103	19	34	644

End points

Top of page

Reporting group title

10PP-LD 3+0d Group

Reporting group description

Reporting group title

10PP-HD 3+0d Group

Reporting group description

This group consisted in infants aged 8-10 weeks at first vaccination enrolled as part the Cohort 2/Step 2 of the study who received 3 doses of the GSK 2189242A (or 10PP) vaccine in its high-dose (HD) formulation and EPI vaccines according to a 3+0 Schedule. That is, subjects received 3 doses of the 10PP vaccine, HD formulation, co-administered with the Tritanrix™-HepB/Hib and Polio Sabin™ at 2-3-4 months of age (Day 0, Month 1 and Month 2), followed by one dose of each of the M-Vac™, Stamaril™ and Polio Sabin™ vaccines administered at approximately 9 months of age. The 10PP vaccine was administered intramuscularly into the right thigh; Tritanrix™-HepB/Hib, M-Vac™ and Stamaril™ were administered intramuscularly into the left thigh; Polio Sabin™ was administered orally.

Reporting group title

Synflorix 3+0d Group

Reporting group description

Reporting group title

Prevnar13 3+0d Group

Reporting group description

Reporting group title

10PP-HD 2+1d Group

Reporting group description

Reporting group title

Synflorix 2+1d Group

Reporting group description

Reporting group title

10PP-HD 1d Group

Reporting group description

Reporting group title

Prevnar13 1d Group

Reporting group description

Primary: Number of subjects with any and Grade 3 solicited local symptoms and Grade 3 solicited local symptoms with relationship to vaccination – For Step 1/Cohort 1 subjects

Top of page

End point title

Number of subjects with any and Grade 3 solicited local symptoms and Grade 3 solicited local symptoms with relationship to vaccination – For Step 1/Cohort 1 subjects ^[1] ^[2]

End point description

Assessed local symptoms were pain, redness and swelling. Any = Occurrence of the specified solicited local symptom, regardless of intensity. Grade 3 Pain = Crying when limb was moved/spontaneously painful. Grade 3 Redness/Swelling = Redness/swelling at injection site larger than (>) 30 millimeters (mm). All solicited local symptoms were systematically considered by the investigators as causally related to vaccination. Primary results correspond to results for occurrences of Grade 3 symptoms. This outcome concerns subjects enrolled in Cohort 1/Step 1.

End point type

Primary

End point timeframe

Within the 4-day (Days 0-3) period post vaccination with pneumococcal vaccine (10PP vaccine or Prevnar 13™)

Notes
[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: The analysis of the primary endpoint was descriptive i.e. no statistical hypothesis test was performed.
[2] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Cohort 1 subjects participated in Step 1 . Cohort 2 subjects participated in Step 2. Please, refer to the title of the endpoint: Statistics are presented only for the groups belonging to the concerned Cohort/Step and the vaccination schedule.

End point values	10PP-HD 1d Group	Prevnar13 1d Group
Number of subjects analysed	60	60
Units: Subjects
Any Pain	0	0
Grade 3 Pain	0	0
Any Redness	0	0
Grade 3 Redness	0	0
Any Swelling	1	0
Grade 3 Swelling	1	0

No statistical analyses for this end point

Primary: Number of subjects with any and Grade 3 solicited general symptoms with and without relationship to vaccination – For Step 1/Cohort 1 subjects

Top of page

End point title

Number of subjects with any and Grade 3 solicited general symptoms with and without relationship to vaccination – For Step 1/Cohort 1 subjects ^[3] ^[4]

End point description

Assessed solicited general symptoms were Drowsiness, Fever (axillary temperature higher than [≥] 37.5 degrees Celsius [°C]), Irritability/Fussiness and Loss of appetite. Any = Occurrence of the specified solicited general symptom, regardless of intensity and relationship to vaccination. Related = Occurrence of the specified symptom assessed by the investigator as causally related to vaccination. Grade 3 Drowsiness = Drowsiness that prevented normal activity. Grade 3 Fever = Axillary temperature higher than (>) 39.5°C. Grade 3 Irritability/fussiness = Crying that could not be comforted/prevented normal activity. Grade 3 Loss of appetite = Subject did not eat at all. Primary results correspond to results for occurrences of Grade 3 symptoms assessed as related to vaccination. This outcome concerns subjects enrolled in Cohort 1/Step 1.

End point type

Primary

End point timeframe

Within the 4-day (Days 0-3) period post vaccination with pneumococcal vaccine (10PP vaccine or Prevnar 13™)

Notes
[3] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: The scope of this primary end point was descriptive, no statistical hypothesis test was performed.
[4] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Cohort 1 subjects participated in Step 1 . Cohort 2 subjects participated in Step 2. Please, refer to the title of the endpoint: Statistics are presented only for the groups belonging to the concerned Cohort/Step and the vaccination schedule.

End point values	10PP-HD 1d Group	Prevnar13 1d Group
Number of subjects analysed	60	60
Units: Subjects
Any Drowsiness	0	0
Grade 3 Drowsiness	0	0
Related Drowsiness	0	0
Grade 3 & Related Drowsiness	0	0
Any Fever	4	2
Grade 3 Fever	0	0
Related Fever	1	1
Grade 3 & Related Fever	0	0
Any Irritability/Fussiness	0	0
Grade 3 Irritability/Fussiness	0	0
Related Irritability/Fussiness	0	0
Grade 3 & Related Irritability/Fussiness	0	0
Any Loss of appetite	1	0
Grade 3 Loss of appetite	0	0
Related Loss of appetite	0	0
Grade 3 & Related Loss of appetite	0	0

No statistical analyses for this end point

Primary: Number of subjects with any and Grade 3 unsolicited adverse events (AEs) with and without relationship to vaccination - For Step 1/Cohort 1 subjects

Top of page

End point title

Number of subjects with any and Grade 3 unsolicited adverse events (AEs) with and without relationship to vaccination - For Step 1/Cohort 1 subjects ^[5] ^[6]

End point description

An unsolicited AE is any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. For marketed medicinal products, this also includes failure to produce expected benefits (i.e. lack of efficacy), abuse or misuse. Any = Occurrence of AE, regardless of intensity or relationship to vaccination. Grade 3 = Occurrence of AE which prevented normal activities. Related = Occurrence of AE assessed by the investigator as causally related to vaccination. Primary results correspond to results for occurrences of Grade 3 unsolicited AE(s) assessed as related to vaccination. This outcome concerns subjects enrolled in Cohort 1/Step 1.

End point type

Primary

End point timeframe

Within the 31-day (Days 0-30) period post vaccination with pneumococcal vaccine (10PP vaccine or Prevnar 13™)

Notes
[5] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: The scope of this primary end point was descriptive, no statistical hypothesis test was performed.
[6] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Cohort 1 subjects participated in Step 1 . Cohort 2 subjects participated in Step 2. Please, refer to the title of the endpoint: Statistics are presented only for the groups belonging to the concerned Cohort/Step and the vaccination schedule.

End point values	10PP-HD 1d Group	Prevnar13 1d Group
Number of subjects analysed	60	60
Units: Subjects
Any unsolicited AE(s)	13	7
Grade 3 unsolicited AE(s)	0	0
Related unsolicited AE(s)	0	0
Grade 3 and related unsolicited AE(s)	0	0

No statistical analyses for this end point

Primary: Number of subjects with any serious adverse events (SAEs) and with SAE(s) with relationship to vaccination - For Step 1/Cohort 1 subjects

Top of page

End point title

Number of subjects with any serious adverse events (SAEs) and with SAE(s) with relationship to vaccination - For Step 1/Cohort 1 subjects ^[7] ^[8]

End point description

SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity. These should also be considered serious: invasive or malignant cancers, intensive treatment in an emergency room or at home for allergic bronchospasm, blood dyscrasias or convulsions that do not result in hospitalisation. Any = Occurrence of an SAE, regardless of relationship to vaccination. Related = Occurrence of an SAE assessed by the investigator as causally related to vaccination. Primary results correspond to results for occurrences of SAE(s) assessed as related to vaccination. This outcome concerns subjects enrolled in Cohort 1/Step 1.

End point type

Primary

End point timeframe

From Day 0 to Month 1

Notes
[7] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: The scope of this primary end point was descriptive, no statistical hypothesis test was performed.
[8] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Cohort 1 subjects participated in Step 1 . Cohort 2 subjects participated in Step 2. Please, refer to the title of the endpoint: Statistics are presented only for the groups belonging to the concerned Cohort/Step and the vaccination schedule.

End point values	10PP-HD 1d Group	Prevnar13 1d Group
Number of subjects analysed	60	60
Units: Subjects
Any SAE(s)	0	0
SAE(s) related to vaccination	0	0

No statistical analyses for this end point

Primary: Number of subjects with non-vaccine serotypes of Streptococcus pneumoniae (S. pn.) in the nasopharynx – For Cohort 2/Step 2, subjects receiving the 3+0 Schedule

Top of page

End point title

Number of subjects with non-vaccine serotypes of Streptococcus pneumoniae (S. pn.) in the nasopharynx – For Cohort 2/Step 2, subjects receiving the 3+0 Schedule ^[9]

End point description

Any serotype belonging to the same serogroup as the serotypes of the pneumococcal vaccine administered (10PP vaccine, or Synflorix™), but different from 10 vaccine pneumococcal serotypes, was considered for this analysis of carriage. Serotypes were identified through cultures and serotyping of the isolates.

End point type

Primary

End point timeframe

At 1, 5 and 8 months (Mth) post-Dose 3 of pneumococcal vaccine administered (10PP vaccine, or Synflorix™)

Notes
[9] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Cohort 1 subjects participated in Step 1 . Cohort 2 subjects participated in Step 2. Please, refer to the title of the endpoint: Statistics are presented only for the groups belonging to the concerned Cohort/Step and the vaccination schedule.

End point values	10PP-LD 3+0d Group	10PP-HD 3+0d Group	Synflorix 3+0d Group
Number of subjects analysed	193	194	196
Units: Subjects
1 Mth post dose 3 (N=193, 194, 196)	154	137	145
5 Mth post dose 3 (N=193, 192, 194)	148	149	159
8 Mth post dose 3 (N=189, 189, 194)	151	154	159

VE-10PP-LD 3+0d vs Synflorix 3+0d- 1M post-Dose3

Statistical analysis description

The analysis aimed to compare occurrences in terms of percentage of subjects with positive nasopharyngeal sample out of the number of subjects with swabs cultured, between 2 groups, one month (M) post-dose 3 of pneumococcal vaccine administered (10PP vaccine or Synflorix™). Vaccine Efficacy (VE) was calculated as 1 minus Relative Risk (i.e. investigational vaccine over control vaccine))*100].

Comparison groups

10PP-LD 3+0d Group v Synflorix 3+0d Group

Number of subjects included in analysis

389

Analysis specification

Pre-specified

Analysis type

equivalence

Method

Parameter type

Point estimate

-7.9

Confidence interval

level

95%

sides

2-sided

lower limit

-36.3

upper limit

14.6

VE-10PP-LD 3+0d vs Synflorix 3+0d- 5M post-Dose3

Statistical analysis description

The analysis aimed to compare occurrences in terms of percentage of subjects with positive nasopharyngeal sample out of the number of subjects with swabs cultured, between 2 groups, five months (M) post-dose 3 of pneumococcal vaccine administered (10PP vaccine or Synflorix™). Vaccine Efficacy (VE) was calculated as 1 minus Relative Risk (i.e. investigational vaccine over control vaccine))*100].

Comparison groups

10PP-LD 3+0d Group v Synflorix 3+0d Group

Number of subjects included in analysis

389

Analysis specification

Pre-specified

Analysis type

equivalence

Method

Parameter type

Point estimate

6.4

Confidence interval

level

95%

sides

2-sided

lower limit

-17.8

upper limit

25.7

VE-10PP-LD 3+0d vs Synflorix 3+0d- 8M post-Dose3

Statistical analysis description

The analysis aimed to compare occurrences in terms of percentage of subjects with positive nasopharyngeal sample out of the number of subjects with swabs cultured, between 2 groups, eight months (M) post-dose 3 of pneumococcal vaccine administered (10PP vaccine or Synflorix™). Vaccine Efficacy (VE) was calculated as 1 minus Relative Risk (i.e. investigational vaccine over control vaccine))*100].

Comparison groups

10PP-LD 3+0d Group v Synflorix 3+0d Group

Number of subjects included in analysis

389

Analysis specification

Pre-specified

Analysis type

equivalence

Method

Parameter type

Point estimate

2.5

Confidence interval

level

95%

sides

2-sided

lower limit

-22.6

upper limit

22.5

VE-10PP-HD 3+0d vs Synflorix 3+0d- 1M post-Dose3

Statistical analysis description

Comparison groups

Synflorix 3+0d Group v 10PP-HD 3+0d Group

Number of subjects included in analysis

390

Analysis specification

Pre-specified

Analysis type

equivalence

Method

Parameter type

Point estimate

4.5

Confidence interval

level

95%

sides

2-sided

lower limit

-21.4

upper limit

VE-10PP-HD 3+0d vs Synflorix 3+0d- 5M post-Dose3

Statistical analysis description

The analysis aimed to compare occurrences in terms of percentage of subjects with positive nasopharyngeal sample out of the number of subjects with swabs cultured, between 2 groups, five months (M) post-dose 3 of pneumococcal vaccine administered (10PP vaccine or Synflorix™). Vaccine Efficacy (VE) was calculated as 1 minus Relative Risk (i.e. investigational vaccine over control vaccine))*100].

Comparison groups

10PP-HD 3+0d Group v Synflorix 3+0d Group

Number of subjects included in analysis

390

Analysis specification

Pre-specified

Analysis type

equivalence

Method

Parameter type

Point estimate

5.3

Confidence interval

level

95%

sides

2-sided

lower limit

-19.2

upper limit

24.8

VE-10PP-HD 3+0d vs Synflorix 3+0d- 8M post-Dose3

Statistical analysis description

The analysis aimed to compare occurrences in terms of percentage of subjects with positive nasopharyngeal sample out of the number of subjects with swabs cultured, between 2 groups, eight months (M) post-dose 3 of pneumococcal vaccine administered (10PP vaccine or Synflorix™). Vaccine Efficacy (VE) was calculated as 1 minus Relative Risk (i.e. investigational vaccine over control vaccine))*100].

Comparison groups

10PP-HD 3+0d Group v Synflorix 3+0d Group

Number of subjects included in analysis

390

Analysis specification

Pre-specified

Analysis type

equivalence

Method

Parameter type

Point estimate

0.6

Confidence interval

level

95%

sides

2-sided

lower limit

-24.9

upper limit

20.9

Primary: Number of subjects with non-vaccine serotypes of Streptococcus pneumoniae (S. pn.) in the nasopharynx – For Cohort 2/Step 2, subjects receiving the 2+1 Schedule

Top of page

End point title

Number of subjects with non-vaccine serotypes of Streptococcus pneumoniae (S. pn.) in the nasopharynx – For Cohort 2/Step 2, subjects receiving the 2+1 Schedule ^[10]

End point description

Any serotype belonging to the same serogroup as the serotypes of the pneumococcal vaccine administered (10PP vaccine or Synflorix™), but different from10 vaccine pneumococcal serotypes, was considered for this analysis of carriage. Serotypes were identified through cultures and serotyping of the isolates.

End point type

Primary

End point timeframe

At 1 and 5 months (Mth) post-Dose 2, and at 3 months post-Dose 3 of the pneumococcal vaccine administered (10PP vaccine or Synflorix™)

Notes
[10] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Cohort 1 subjects participated in Step 1 . Cohort 2 subjects participated in Step 2. Please, refer to the title of the endpoint: Statistics are presented only for the groups belonging to the concerned Cohort/Step and the vaccination schedule.

End point values	10PP-HD 2+1d Group	Synflorix 2+1d Group
Number of subjects analysed	197	197
Units: Subjects
1 Mth post dose 2 (N=197, 197)	142	152
5 Mth post dose 2 (N=189, 194)	146	160
3 Mth post dose 3 (N=190, 193)	165	162

VE-10PP-HD 2+1d vs Synflorix 2+1d- 1M post-Dose2

Statistical analysis description

The analysis aimed to compare occurrences in terms of percentage of subjects with positive nasopharyngeal sample out of the number of subjects with swabs cultured, between 2 groups, one month (M) post-dose 2 of pneumococcal vaccine administered (10PP vaccine or Synflorix™). Vaccine Efficacy (VE) was calculated as 1 minus Relative Risk (i.e. investigational vaccine over control vaccine))*100].

Comparison groups

10PP-HD 2+1d Group v Synflorix 2+1d Group

Number of subjects included in analysis

394

Analysis specification

Pre-specified

Analysis type

equivalence

Method

Parameter type

Point estimate

6.6

Confidence interval

level

95%

sides

2-sided

lower limit

-18.2

upper limit

26.2

VE-10PP-HD 2+1d vs Synflorix 2+1d- 5M post-Dose2

Statistical analysis description

The analysis aimed to compare occurrences in terms of percentage of subjects with positive nasopharyngeal sample out of the number of subjects with swabs cultured, between 2 groups, five months (M) post-dose 2 of pneumococcal vaccine administered (10PP vaccine or Synflorix™). Vaccine Efficacy (VE) was calculated as 1 minus Relative Risk (i.e. investigational vaccine over control vaccine))*100].

Comparison groups

10PP-HD 2+1d Group v Synflorix 2+1d Group

Number of subjects included in analysis

394

Analysis specification

Pre-specified

Analysis type

equivalence

Method

Parameter type

Point estimate

6.3

Confidence interval

level

95%

sides

2-sided

lower limit

-18

upper limit

25.7

VE-10PP-HD 2+1d vs Synflorix 2+1d- 3M post-Dose3

Statistical analysis description

The analysis aimed to compare occurrences in terms of percentage of subjects with positive nasopharyngeal sample out of the number of subjects with swabs cultured, between 2 groups, three months (M) post-dose 3 of pneumococcal vaccine administered (10PP vaccine or Synflorix™). Vaccine Efficacy (VE) was calculated as 1 minus Relative Risk (i.e. investigational vaccine over control vaccine))*100].

Comparison groups

10PP-HD 2+1d Group v Synflorix 2+1d Group

Number of subjects included in analysis

394

Analysis specification

Pre-specified

Analysis type

equivalence

Method

Parameter type

Point estimate

-3.5

Confidence interval

level

95%

sides

2-sided

lower limit

-29.3

upper limit

17.2

Secondary: Number of subjects with haematological or biochemical abnormalities with respect to normal laboratory ranges – For Cohort 1/Step 1 subjects

Top of page

End point title

Number of subjects with haematological or biochemical abnormalities with respect to normal laboratory ranges – For Cohort 1/Step 1 subjects ^[11]

End point description

Assessed biochemical and haematological parameters were: Haemoglobin (Hgb), White cell count (WBC), Platelet counts, Alanine aminotransferase (ALT) and Creatinine (CREA). Per parameter, it was assessed whether subjects had laboratory values below normal, normal, or above normal range. Below = value below the laboratory reference range defined for the specified time point and laboratory parameter. Within = value within the laboratory reference range defined for the specified time point and laboratory parameter. Above = value above the laboratory reference range defined for the specified time point and laboratory parameter. Unknown = value unknown for the specified time point and laboratory parameter. This outcome concerns subjects enrolled in Cohort 1/Step 1.

End point type

Secondary

End point timeframe

At Month 1, or 1 month post vaccination with pneumococcal vaccine (10PP vaccine or Prevnar 13™)

Notes
[11] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Cohort 1 subjects participated in Step 1 . Cohort 2 subjects participated in Step 2. Please, refer to the title of the endpoint: Statistics are presented only for the groups belonging to the concerned Cohort/Step and the vaccination schedule.

End point values	10PP-HD 1d Group	Prevnar13 1d Group
Number of subjects analysed	60	60
Units: Subjects
ALT – Status: Unknown	0	0
ALT – Status: Below	0	0
ALT – Status: Within	60	57
ALT – Status: Above	0	3
CREA – Status: Unknown	0	0
CREA – Status: Below	0	0
CREA – Status: Within	60	60
CREA – Status: Above	0	0
Hgb – Status: Unknown	0	0
Hgb – Status: Below	2	2
Hgb – Status: Within	57	56
Hgb – Status: Above	1	2
Platelets – Status: Unknown	0	0
Platelets – Status: Below	0	0
Platelets – Status: Within	59	60
Platelets – Status: Above	1	0
WBC – Status: Unknown	0	0
WBC – Status: Below	0	0
WBC – Status: Within	60	60
WBC – Status: Above	0	0

No statistical analyses for this end point

Secondary: Number of subjects with serious adverse events (SAEs) – For Step 1/Cohort 1 subjects

Top of page

End point title

Number of subjects with serious adverse events (SAEs) – For Step 1/Cohort 1 subjects ^[12]

End point description

SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity. These should also be considered serious: invasive or malignant cancers, intensive treatment in an emergency room or at home for allergic bronchospasm, blood dyscrasias or convulsions that do not result in hospitalisation. Any = Occurrence of an SAE, regardless of relationship to vaccination. This outcome concerns subjects enrolled in Cohort 1/Step 1.

End point type

Secondary

End point timeframe

From Day 0 to Month 6

Notes
[12] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Cohort 1 subjects participated in Step 1 . Cohort 2 subjects participated in Step 2. Please, refer to the title of the endpoint: Statistics are presented only for the groups belonging to the concerned Cohort/Step and the vaccination schedule.

End point values	10PP-HD 1d Group	Prevnar13 1d Group
Number of subjects analysed	60	60
Units: Subjects
Any SAE(s)	0	0

No statistical analyses for this end point

Secondary: Antibody concentrations against pneumococcal pneumolysin toxoid (Ply) and pneumococcal histidine triad protein D (PhtD) proteins – For Cohort 1/Step 1 subjects

Top of page

End point title

Antibody concentrations against pneumococcal pneumolysin toxoid (Ply) and pneumococcal histidine triad protein D (PhtD) proteins – For Cohort 1/Step 1 subjects ^[13]

End point description

Anti-Ply and anti-PhtD antibody concentrations were measured by Multiplex immunoassay and expressed as geometric mean concentrations (GMCs), in Luminex Units per milliliter (LU/mL). Cut-off of the assay were concentrations higher than or equal to (≥) 599 LU/mL for anti-Ply antibodies and ≥ 391 LU/mL for anti-PhtD antibodies. This outcome concerns subjects enrolled in Cohort 1/Step 1.

End point type

Secondary

End point timeframe

At Month 1, or 1 month post vaccination with pneumococcal vaccine (10PP vaccine or Prevnar 13™)

Notes
[13] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Cohort 1 subjects participated in Step 1 . Cohort 2 subjects participated in Step 2. Please, refer to the title of the endpoint: Statistics are presented only for the groups belonging to the concerned Cohort/Step and the vaccination schedule.

End point values	10PP-HD 1d Group	Prevnar13 1d Group
Number of subjects analysed	52	51
Units: LU/mL
geometric mean (confidence interval 95%)
Anti-Ply	22794.9 (17570.1 to 29573.3)	8510.3 (6668.5 to 10860.8)
Anti-PhtD	31326.3 (26293.9 to 37321.8)	16810 (13516.3 to 20906.4)

No statistical analyses for this end point

Secondary: Antibody concentrations against Protein D (PD) – For Cohort 1/Step 1 subjects

Top of page

End point title

Antibody concentrations against Protein D (PD) – For Cohort 1/Step 1 subjects ^[14]

End point description

Anti-PD antibody concentrations were measured by Multiplex immunoassay, expressed as geometric mean concentrations (GMCs), in Luminex Units per milliliter (LU/mL). The cut-off of the assay was an anti-PD antibody concentration higher than or equal to (≥) 112 LU/mL. This outcome concerns subjects enrolled in Cohort 1/Step 1.

End point type

Secondary

End point timeframe

At Month 1, or 1 month post vaccination with pneumococcal vaccine (10PP vaccine or Prevnar 13™)

Notes
[14] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Cohort 1 subjects participated in Step 1 . Cohort 2 subjects participated in Step 2. Please, refer to the title of the endpoint: Statistics are presented only for the groups belonging to the concerned Cohort/Step and the vaccination schedule.

End point values	10PP-HD 1d Group	Prevnar13 1d Group
Number of subjects analysed	52	51
Units: LU/mL
geometric mean (confidence interval 95%)
Anti-PD	137.5 (108.4 to 174.4)	65.1 (58.2 to 72.8)

No statistical analyses for this end point

Secondary: Antibody concentrations against vaccine serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F – For Cohort 1/Step 1 subjects

Top of page

End point title

Antibody concentrations against vaccine serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F – For Cohort 1/Step 1 subjects ^[15]

End point description

Antibody concentrations were measured by 22F-inhibition Enzyme-Linked ImmunoSorbent Assay (ELISA), expressed as geometric mean concentrations (GMCs), in micrograms per milliliter (µg/mL). The cut-off of the assay was an antibody concentration higher than or equal to (≥) 0.05 µg/mL. This outcome concerns subjects enrolled in Cohort 1/Step 1.

End point type

Secondary

End point timeframe

At Month 1, or 1 month post vaccination with pneumococcal vaccine (10PP vaccine or Prevnar 13™)

Notes
[15] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Cohort 1 subjects participated in Step 1 . Cohort 2 subjects participated in Step 2. Please, refer to the title of the endpoint: Statistics are presented only for the groups belonging to the concerned Cohort/Step and the vaccination schedule.

End point values	10PP-HD 1d Group	Prevnar13 1d Group
Number of subjects analysed	52	51
Units: µg/mL
geometric mean (confidence interval 95%)
Anti-1 antibodies	1.71 (1.33 to 2.22)	3.12 (2.44 to 4.01)
Anti-4 antibodies	4.8 (3.75 to 6.14)	4.17 (3.33 to 5.21)
Anti-5 antibodies	1.17 (0.88 to 1.55)	1.47 (1.08 to 1.99)
Anti-6B antibodies	0.5 (0.34 to 0.73)	1.57 (0.98 to 2.51)
Anti-7F antibodies	2.44 (1.99 to 2.98)	6.11 (4.44 to 8.41)
Anti-9V antibodies	0.89 (0.71 to 1.12)	2.41 (1.87 to 3.26)
Anti-14 antibodies	1.88 (1.39 to 2.53)	3.77 (2.61 to 5.43)
Anti-18C antibodies	7.58 (5.43 to 10.57)	4.82 (3.46 to 6.71)
Anti-19F antibodies	7.82 (5.84 to 10.46)	5.95 (4.48 to 7.9)
Anti-23F antibodies	0.31 (0.21 to 0.46)	1.11 (0.74 to 1.67)

No statistical analyses for this end point

Secondary: Antibody concentrations against vaccine serotypes 3, 6A and 19A – For Cohort 1/Step 1 subjects

Top of page

End point title

Antibody concentrations against vaccine serotypes 3, 6A and 19A – For Cohort 1/Step 1 subjects ^[16]

End point description

End point type

Secondary

End point timeframe

At Month 1, or 1 month post vaccination with pneumococcal vaccine (10PP vaccine or Prevnar 13™)

Notes
[16] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Cohort 1 subjects participated in Step 1 . Cohort 2 subjects participated in Step 2. Please, refer to the title of the endpoint: Statistics are presented only for the groups belonging to the concerned Cohort/Step and the vaccination schedule.

End point values	10PP-HD 1d Group	Prevnar13 1d Group
Number of subjects analysed	52	51
Units: µg/mL
geometric mean (confidence interval 95%)
Anti-3 antibodies	0.25 (0.14 to 0.46)	2.35 (1.77 to 3.12)
Anti-6A antibodies	0.18 (0.12 to 0.27)	1.36 (0.96 to 1.93)
Anti-19A antibodies	1.38 (0.91 to 2.1)	5.51 (4.02 to 7.55)

No statistical analyses for this end point

Secondary: Titers for opsonophagocytic activity against vaccine serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F – For Cohort 1/Step 1 subjects

Top of page

End point title

Titers for opsonophagocytic activity against vaccine serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F – For Cohort 1/Step 1 subjects ^[17]

End point description

The cut-off of the assay was a titer for opsonophagocytic activity higher than or equal to (≥) 8. This outcome concerns subjects enrolled in Cohort 1/Step 1.

End point type

Secondary

End point timeframe

At Month 1, or 1 month post vaccination with pneumococcal vaccine (10PP vaccine or Prevnar 13™)

Notes
[17] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Cohort 1 subjects participated in Step 1 . Cohort 2 subjects participated in Step 2. Please, refer to the title of the endpoint: Statistics are presented only for the groups belonging to the concerned Cohort/Step and the vaccination schedule.

End point values	10PP-HD 1d Group	Prevnar13 1d Group
Number of subjects analysed	52	51
Units: Titers
geometric mean (confidence interval 95%)
OPSONO-1 (N=52;50)	17.2 (11.2 to 26.4)	112.8 (71.9 to 177)
OPSONO-4 (N=52;51)	2818.9 (2009.7 to 3953.8)	4162.3 (3123.9 to 5545.9)
OPSONO-5 (N=52;49)	9 (6.4 to 12.7)	89.8 (55.8 to 144.5)
OPSONO-6B (N=50;51)	345.3 (171.4 to 695.5)	5082.5 (3700.2 to 6981.2)
OPSONO-7F (N=52;51)	6214 (5217.1 to 7401.4)	17781 (14034.2 to 22528)
OPSONO-9V (N=52;51)	2880.8 (2264.8 to 3664.5)	12687.8 (9188.2 to 17520.2)
OPSONO-14 (N=51;51)	1116.1 (715.5 to 1741)	5985.9 (4313.1 to 8307.4)
OPSONO-18C (N=52;49)	3955.4 (3027.7 to 5167.2)	2799.8 (1931.1 to 4059.2)
OPSONO-19F (N=52;51)	862.9 (529.2 to 1407)	452.8 (276.2 to 742.2)
OPSONO-23F (N=51;51)	2756.7 (1638 to 4639.5)	12652.4 (8076 to 19822.2)

No statistical analyses for this end point

Secondary: Titers for opsonophagocytic activity against vaccine serotypes 3, 6A and 19A – For Cohort 1/Step 1 subjects

Top of page

End point title

Titers for opsonophagocytic activity against vaccine serotypes 3, 6A and 19A – For Cohort 1/Step 1 subjects ^[18]

End point description

The cut-off of the assay was a titer for opsonophagocytic activity higher than or equal to (≥) 8. This outcome concerns subjects enrolled in Cohort 1/Step 1.

End point type

Secondary

End point timeframe

At Month 1, or 1 month post vaccination with pneumococcal vaccine (10PP vaccine or Prevnar 13™)

Notes
[18] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Cohort 1 subjects participated in Step 1 . Cohort 2 subjects participated in Step 2. Please, refer to the title of the endpoint: Statistics are presented only for the groups belonging to the concerned Cohort/Step and the vaccination schedule.

End point values	10PP-HD 1d Group	Prevnar13 1d Group
Number of subjects analysed	51	51
Units: Titers
geometric mean (confidence interval 95%)
OPSONO-3 (N=51;51)	10.1 (6.5 to 15.8)	152.5 (120.4 to 193.2)
OPSONO-6A (N=47;51)	212.7 (110.4 to 410)	8488.8 (5984.2 to 12041.8)
OPSONO-19A (N=49;50)	461.7 (277.2 to 769)	970.3 (701 to 1342.9)

No statistical analyses for this end point

Secondary: Concentrations of antibodies inhibiting pneumococcal pneumolysin toxoid (Ply) haemolysis activity, or Hem-Ply antibodies – For Cohort 1/Step 1 subjects

Top of page

End point title

Concentrations of antibodies inhibiting pneumococcal pneumolysin toxoid (Ply) haemolysis activity, or Hem-Ply antibodies – For Cohort 1/Step 1 subjects ^[19]

End point description

Concentrations of Hem-Ply antibodies were expressed as geometric mean titers . The cut-off of the assay was an Hem-Ply antibody titer ≥ 140. This outcome concerns subjects enrolled in Cohort 1/Step 1.

End point type

Secondary

End point timeframe

At Month 1, or 1 month post vaccination with pneumococcal vaccine (10PP vaccine or Prevnar 13™)

Notes
[19] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Cohort 1 subjects participated in Step 1 . Cohort 2 subjects participated in Step 2. Please, refer to the title of the endpoint: Statistics are presented only for the groups belonging to the concerned Cohort/Step and the vaccination schedule.

End point values	10PP-HD 1d Group	Prevnar13 1d Group
Number of subjects analysed	52	51
Units: Titers
geometric mean (confidence interval 95%)
Hem-Ply antibodies	682.3 (562.8 to 827.3)	534 (439.4 to 648.9)

No statistical analyses for this end point

Secondary: Number of subjects with any and Grade 3 solicited local symptoms – For Cohort2/Step 2 subjects receiving the 3+0 Schedule

Top of page

End point title

Number of subjects with any and Grade 3 solicited local symptoms – For Cohort2/Step 2 subjects receiving the 3+0 Schedule ^[20]

End point description

End point type

Secondary

End point timeframe

Within the 4-day (Days 0-3) periods post vaccination with 3 doses of pneumococcal vaccine (10PP vaccine, Synflorix™ or Prevnar 13™), across doses

Notes
[20] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Cohort 1 subjects participated in Step 1 . Cohort 2 subjects participated in Step 2. Please, refer to the title of the endpoint: Statistics are presented only for the groups belonging to the concerned Cohort/Step and the vaccination schedule.

End point values	10PP-LD 3+0d Group	10PP-HD 3+0d Group	Synflorix 3+0d Group	Prevnar13 3+0d Group
Number of subjects analysed	200	200	200	200
Units: Subjects
Any pain	108	121	123	115
Grade 3 pain	0	1	0	0
Any redness	8	7	9	5
Grade 3 redness	0	1	1	0
Any swelling	30	45	40	37
Grade 3 swelling	7	10	17	7

No statistical analyses for this end point

Secondary: Number of subjects with any and Grade 3 solicited local symptoms – For Cohort2/Step 2 subjects receiving the 2+1 Schedule

Top of page

End point title

Number of subjects with any and Grade 3 solicited local symptoms – For Cohort2/Step 2 subjects receiving the 2+1 Schedule ^[21]

End point description

End point type

Secondary

End point timeframe

Within the 4-day (Days 0-3) periods post vaccination with the 2 first doses of pneumococcal vaccine (10PP vaccine or Synflorix™), across doses

Notes
[21] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Cohort 1 subjects participated in Step 1 . Cohort 2 subjects participated in Step 2. Please, refer to the title of the endpoint: Statistics are presented only for the groups belonging to the concerned Cohort/Step and the vaccination schedule.

End point values	10PP-HD 2+1d Group	Synflorix 2+1d Group
Number of subjects analysed	200	200
Units: Subjects
Any pain	97	102
Grade 3 pain	1	1
Any redness	3	5
Grade 3 redness	0	0
Any swelling	35	31
Grade 3 swelling	9	4

No statistical analyses for this end point

Secondary: Number of subjects with any and Grade 3 solicited local symptoms – For Cohort2/Step 2 subjects receiving the 2+1 Schedule

Top of page

End point title

Number of subjects with any and Grade 3 solicited local symptoms – For Cohort2/Step 2 subjects receiving the 2+1 Schedule ^[22]

End point description

End point type

Secondary

End point timeframe

Within the 4-day (Days 0-3) period post vaccination with Dose 3 of pneumococcal vaccine (10PP vaccine or Synflorix™)

Notes
[22] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Cohort 1 subjects participated in Step 1 . Cohort 2 subjects participated in Step 2. Please, refer to the title of the endpoint: Statistics are presented only for the groups belonging to the concerned Cohort/Step and the vaccination schedule.

End point values	10PP-HD 2+1d Group	Synflorix 2+1d Group
Number of subjects analysed	191	195
Units: Subjects
Any pain	21	26
Grade 3 pain	0	0
Any redness	0	0
Grade 3 redness	0	0
Any swelling	4	8
Grade 3 swelling	1	3

No statistical analyses for this end point

Secondary: Number of subjects with any and Grade 3 solicited general symptoms and with solicited general symptoms with relationship to vaccination – For Step 2/Cohort 2 subjects receiving the 3+0 Schedule

Top of page

End point title

Number of subjects with any and Grade 3 solicited general symptoms and with solicited general symptoms with relationship to vaccination – For Step 2/Cohort 2 subjects receiving the 3+0 Schedule ^[23]

End point description

Assessed solicited general symptoms were Drowsiness, Fever (axillary temperature higher than [≥] 37.5 degrees Celsius [°C]), Irritability/Fussiness and Loss of appetite. Any = Occurrence of the specified solicited general symptom, regardless of intensity. Related = Occurrence of the specified symptom assessed by the investigators as causally related to vaccination. Grade 3 Drowsiness = Drowsiness that prevented normal activity. Grade 3 Fever = Axillary temperature higher than (>) 39.5°C. Grade 3 Irritability/fussiness = Crying that could not be comforted/prevented normal activity. Grade 3 Loss of appetite = Subject did not eat at all. This outcome concerns Step 2/Cohort 2 subjects receiving the 3+0 Schedule.

End point type

Secondary

End point timeframe

Within the 4-day (Days 0-3) periods post vaccination with 3 doses of pneumococcal vaccine (10PP vaccine, Synflorix™ or Prevnar 13™), across doses

Notes
[23] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Cohort 1 subjects participated in Step 1 . Cohort 2 subjects participated in Step 2. Please, refer to the title of the endpoint: Statistics are presented only for the groups belonging to the concerned Cohort/Step and the vaccination schedule.

End point values	10PP-LD 3+0d Group	10PP-HD 3+0d Group	Synflorix 3+0d Group	Prevnar13 3+0d Group
Number of subjects analysed	200	200	200	200
Units: Subjects
Any Drowsiness	43	46	38	44
Grade 3 Drowsiness	0	0	0	0
Related Drowsiness	43	45	38	43
Any Irritability/fussiness	139	133	141	136
Grade 3 Irritability/fussiness	6	4	4	7
Related Irritability/fussiness	138	132	138	136
Any Loss of appetite	32	30	27	34
Grade 3 Loss of appetite	0	0	1	0
Related Loss of appetite	32	29	26	34
Any Fever	104	100	105	106
Grade 3 Fever	0	0	0	0
Related Fever	102	100	104	104

No statistical analyses for this end point

Secondary: Number of subjects with any and Grade 3 solicited general symptoms and with solicited general symptoms with relationship to vaccination – For Step 2/Cohort 2 subjects receiving the 2+1 Schedule

Top of page

End point title

End point description

Assessed solicited general symptoms were Drowsiness, Fever (axillary temperature higher than [≥] 37.5 degrees Celsius [°C]), Irritability/Fussiness and Loss of appetite. Any = Occurrence of the specified solicited general symptom, regardless of intensity. Related = Occurrence of the specified symptom assessed by the investigators as causally related to vaccination. Grade 3 Drowsiness = Drowsiness that prevented normal activity. Grade 3 Fever = Axillary temperature higher than (>) 39.5°C. Grade 3 Irritability/fussiness = Crying that could not be comforted/prevented normal activity. Grade 3 Loss of appetite = Subject did not eat at all. This outcome concerns Step 2/Cohort 2 subjects receiving the 2+1 Schedule.

End point type

Secondary

End point timeframe

Within the 4-day (Days 0-3) periods post vaccination with the 2 first doses of pneumococcal vaccine (10PP vaccine or Synflorix™), across doses

Notes
[24] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Cohort 1 subjects participated in Step 1 . Cohort 2 subjects participated in Step 2. Please, refer to the title of the endpoint: Statistics are presented only for the groups belonging to the concerned Cohort/Step and the vaccination schedule.

End point values	10PP-HD 2+1d Group	Synflorix 2+1d Group
Number of subjects analysed	200	200
Units: Subjects
Any Drowsiness	47	44
Grade 3 Drowsiness	0	0
Related Drowsiness	46	43
Any Fever	92	84
Grade 3 Fever	0	0
Related Fever	89	84
Any Irritability/fussiness	131	128
Grade 3 Irritability/fussiness	1	2
Related Irritability/fussiness	128	126
Any Loss of appetite	24	25
Grade 3 Loss of appetite	0	0
Related Loss of appetite	24	24

No statistical analyses for this end point

Secondary: Number of subjects with any and Grade 3 solicited general symptoms and with solicited general symptoms with relationship to vaccination – For Step 2/Cohort 2 subjects receiving the 2+1 Schedule

Top of page

End point title

End point description

Assessed solicited general symptoms were Drowsiness, Fever (axillary temperature higher than [≥] 37.5 degrees Celsius [°C]), Irritability/Fussiness and Loss of appetite. Any = Occurrence of the specified solicited general symptom, regardless of intensity. Related = Occurrence of the specified symptom assessed by the investigators as causally related to vaccination. Grade 3 Drowsiness = Drowsiness that prevented normal activity. Grade 3 Fever = Axillary temperature higher than (>) 39.5°C. Grade 3 Irritability/fussiness = Crying that could not be comforted/prevented normal activity. Grade 3 Loss of appetite = Subject did not eat at all. This outcome concerns Step 2/Cohort 2 subjects receiving the 2+1 Schedule.

End point type

Secondary

End point timeframe

Within the 4-day (Days 0-3) period post vaccination with Dose 3 of pneumococcal vaccine (10PP vaccine or Synflorix™)

Notes
[25] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Cohort 1 subjects participated in Step 1 . Cohort 2 subjects participated in Step 2. Please, refer to the title of the endpoint: Statistics are presented only for the groups belonging to the concerned Cohort/Step and the vaccination schedule.

End point values	10PP-HD 2+1d Group	Synflorix 2+1d Group
Number of subjects analysed	191	195
Units: Subjects
Any Drowsiness	12	4
Grade 3 Drowsiness	0	0
Related Drowsiness	12	4
Any Fever	32	27
Grade 3 Fever	0	1
Related Fever	30	25
Any Irritability/fussiness	27	19
Grade 3 Irritability/fussiness	0	0
Related Irritability/fussiness	27	19
Any Loss of appetite	3	5
Grade 3 Loss of appetite	0	0
Related Loss of appetite	3	4

No statistical analyses for this end point

Secondary: Number of subjects with any unsolicited adverse events (AEs) – For Step 2/Cohort 2 subjects receiving the 3+0 Schedule

Top of page

End point title

Number of subjects with any unsolicited adverse events (AEs) – For Step 2/Cohort 2 subjects receiving the 3+0 Schedule ^[26]

End point description

An unsolicited AE is any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. For marketed medicinal products, this also includes failure to produce expected benefits (i.e. lack of efficacy), abuse or misuse. Any = Occurrence of an unsolicited AE, regardless of intensity or relationship to vaccination. This outcome concerns Step 2/Cohort 2 subjects receiving the 3+0 Schedule.

End point type

Secondary

End point timeframe

Within the 31-day (Days 0-30) periods post vaccination with 3 doses of pneumococcal vaccine (10PP vaccine, Synflorix™ or Prevnar 13™), across doses

Notes
[26] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Cohort 1 subjects participated in Step 1 . Cohort 2 subjects participated in Step 2. Please, refer to the title of the endpoint: Statistics are presented only for the groups belonging to the concerned Cohort/Step and the vaccination schedule.

End point values	10PP-LD 3+0d Group	10PP-HD 3+0d Group	Synflorix 3+0d Group	Prevnar13 3+0d Group
Number of subjects analysed	200	200	200	200
Units: Subjects
Any AE(s)	113	114	123	114

No statistical analyses for this end point

Secondary: Number of subjects with any unsolicited adverse events (AEs) – For Step 2/Cohort 2 subjects receiving the 2+1 Schedule

Top of page

End point title

Number of subjects with any unsolicited adverse events (AEs) – For Step 2/Cohort 2 subjects receiving the 2+1 Schedule ^[27]

End point description

An unsolicited AE is any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. For marketed medicinal products, this also includes failure to produce expected benefits (i.e. lack of efficacy), abuse or misuse. Any = Occurrence of an unsolicited AE, regardless of intensity or relationship to vaccination. This outcome concerns Step 2/Cohort 2 subjects receiving the 2+1 Schedule.

End point type

Secondary

End point timeframe

Within the 31-day (Days 0-30) periods post vaccination with the 2 first doses of pneumococcal vaccine (10PP vaccine or Synflorix™), across doses

Notes
[27] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Cohort 1 subjects participated in Step 1 . Cohort 2 subjects participated in Step 2. Please, refer to the title of the endpoint: Statistics are presented only for the groups belonging to the concerned Cohort/Step and the vaccination schedule.

End point values	10PP-HD 2+1d Group	Synflorix 2+1d Group
Number of subjects analysed	200	200
Units: Subjects
Any AE(s)	84	95

No statistical analyses for this end point

Secondary: Antibody concentrations against pneumococcal pneumolysin toxoid (Ply) and pneumococcal histidine triad protein D (PhtD) proteins – For Cohort 2/Step 2 subjects receiving the 3+0 Schedule

Top of page

End point title

Antibody concentrations against pneumococcal pneumolysin toxoid (Ply) and pneumococcal histidine triad protein D (PhtD) proteins – For Cohort 2/Step 2 subjects receiving the 3+0 Schedule ^[28]

End point description

Anti-Ply and anti-PhtD antibody concentrations were measured by Enzyme-linked immunosorbent assay (ELISA) immunoassay and expressed as geometric mean concentrations (GMCs), in ELISA Units per milliliter (EL.U/mL). Cut-off of the assay were concentrations higher than or equal to (≥) 12 EL.U/mL for anti-Ply antibodies and ≥ 17 EL.U/mL for anti-PhtD antibodies. This outcome concerns subjects enrolled in Cohort 2/Step 2 who received the 3+0 Schedule.

End point type

Secondary

End point timeframe

At 1, 5 and 8 months (Mth) post-Dose 3 of pneumococcal vaccine administered (10PP vaccine, Synflorix™ or Prevnar 13™)

Notes
[28] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Cohort 1 subjects participated in Step 1 . Cohort 2 subjects participated in Step 2. Please, refer to the title of the endpoint: Statistics are presented only for the groups belonging to the concerned Cohort/Step and the vaccination schedule.

End point values	10PP-LD 3+0d Group	10PP-HD 3+0d Group	Synflorix 3+0d Group	Prevnar13 3+0d Group
Number of subjects analysed	192	195	196	195
Units: EL.U/mL
geometric mean (confidence interval 95%)
Anti-Ply 1 Mth post dose 3 (N=192, 195, 196, 195)	13968.86 (12612.27 to 15471.36)	16771.16 (15267.84 to 18422.51)	451.32 (398.68 to 510.91)	419.47 (377.26 to 466.4)
Anti-Ply 5 Mth post dose 3 (N=191, 192, 195, 190)	11268.35 (9870.36 to 12864.36)	10817.78 (9528.87 to 12281.04)	744.86 (631.27 to 878.89)	637.49 (539.55 to 753.22)
Anti-Ply 8 Mth post dose 3 (N=189, 190, 195, 188)	10512.39 (9249.03 to 11948.33)	10299.57 (9137.48 to 11609.44)	999.39 (861.41 to 1159.49)	884.83 (748.83 to 1045.54)
Anti-PhtD 1 Mth post dose 3 (N=192, 195, 196, 195)	2584.28 (2292.67 to 2912.98)	2188.28 (1934.94 to 2474.8)	334.18 (292.9 to 381.28)	486.01 (419.64 to 562.87)
Anti-PhtD 5 Mth post dose 3 (N=191, 192, 195, 190)	2242.06 (1971.08 to 2550.29)	1498.86 (1311.05 to 1713.57)	936.83 (780.23 to 1124.86)	1419.77 (1196.01 to 1685.4)
Anti-PhtD 8 Mth post dose 3 (N=189, 190, 195, 188)	2608.78 (2318.09 to 2935.92)	2078.35 (1861.91 to 2319.95)	1667.91 (1432.09 to 1942.55)	2380.09 (2118.18 to 2674.39)

No statistical analyses for this end point

Secondary: Antibody concentrations against pneumococcal pneumolysin toxoid (Ply) and pneumococcal histidine triad protein D (PhtD) proteins – For Cohort 2/Step 2 subjects receiving the 2+1 Schedule

Top of page

End point title

Antibody concentrations against pneumococcal pneumolysin toxoid (Ply) and pneumococcal histidine triad protein D (PhtD) proteins – For Cohort 2/Step 2 subjects receiving the 2+1 Schedule ^[29]

End point description

End point type

Secondary

End point timeframe

At 1 and 5 months (Mth) post-Dose 2, and at 3 months post-Dose 3 of the pneumococcal vaccine administered (10PP vaccine or Synflorix™)

Notes
[29] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Cohort 1 subjects participated in Step 1 . Cohort 2 subjects participated in Step 2. Please, refer to the title of the endpoint: Statistics are presented only for the groups belonging to the concerned Cohort/Step and the vaccination schedule.

End point values	10PP-HD 2+1d Group	Synflorix 2+1d Group
Number of subjects analysed	193	193
Units: EL.U/mL
geometric mean (confidence interval 95%)
Anti-Ply 1 Mth post dose 2 (N=193, 193)	11491.54 (10168.1 to 12987.23)	488.79 (427.38 to 559.01)
Anti-Ply 5 Mth post dose 2 (N=189, 191)	7453.65 (6460.7 to 8599.21)	807.67 (676.2 to 964.7)
Anti-Ply 3 Mth post dose 3 (N=190, 190)	17933.07 (15867 to 20268.17)	1114.25 (945.08 to 1313.71)
Anti-PhtD 1 Mth post dose 2 (N=193, 193)	1264.57 (1103.87 to 1448.66)	368.62 (319.88 to 424.79)
Anti-PhtD 5 Mth post dose 2 (N=189, 191)	1448.08 (1253.08 to 1673.41)	1036.53 (853.8 to 1258.36)
Anti-PhtD 3 Mth post dose 3 (N=190, 190)	3250.91 (2956.18 to 3575.02)	1654.79 (1415.54 to 1934.47)

No statistical analyses for this end point

Secondary: Antibody concentrations against Protein D (PD) – For Cohort 2/Step 2 subjects receiving the 3+0 Schedule

Top of page

End point title

Antibody concentrations against Protein D (PD) – For Cohort 2/Step 2 subjects receiving the 3+0 Schedule ^[30]

End point description

Anti-PD antibody concentrations were measured by Enzyme-linked immunosorbent assay (ELISA) immunoassay, expressed as geometric mean concentrations (GMCs), in ELISA Units per milliliter (EL.U/mL). The cut-off of the assay was anti-PD antibody concentration higher than or equal to (≥) 100 EL.U/mL. This outcome concerns subjects enrolled in Cohort 2/Step 2 who received the 3+0 Schedule.

End point type

Secondary

End point timeframe

At 1, 5 and 8 months (Mth) post-Dose 3 of pneumococcal vaccine administered (10PP vaccine, Synflorix™ or Prevnar 13™)

Notes
[30] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Cohort 1 subjects participated in Step 1 . Cohort 2 subjects participated in Step 2. Please, refer to the title of the endpoint: Statistics are presented only for the groups belonging to the concerned Cohort/Step and the vaccination schedule.

End point values	10PP-LD 3+0d Group	10PP-HD 3+0d Group	Synflorix 3+0d Group	Prevnar13 3+0d Group
Number of subjects analysed	191	193	194	189
Units: EL.U/mL
geometric mean (confidence interval 95%)
Anti-PD 1 Mth post dose 3 (N=186, 193, 187, 189)	1922.8 (1739.3 to 2125.6)	1833.8 (1628.5 to 2065)	1990.2 (1765.7 to 2243.3)	84.8 (76.4 to 94.1)
Anti-PD 5 Mth post dose 3 (N=191, 191, 193, 185)	559.2 (496.8 to 629.6)	499.2 (439.9 to 566.5)	609.9 (537 to 692.8)	83.1 (74.9 to 92.2)
Anti-PD 8 Mth post dose 3 (N=187, 190, 194, 187)	324.3 (282.2 to 372.7)	288.2 (248.5 to 334.2)	344.2 (300.6 to 394.2)	69.2 (63.6 to 75.3)

No statistical analyses for this end point

Secondary: Antibody concentrations against Protein D (PD) – For Cohort 2/Step 2 subjects receiving the 2+1 Schedule

Top of page

End point title

Antibody concentrations against Protein D (PD) – For Cohort 2/Step 2 subjects receiving the 2+1 Schedule ^[31]

End point description

End point type

Secondary

End point timeframe

At 1 and 5 months (Mth) post-Dose 2, and at 3 months post-Dose 3 of the pneumococcal vaccine administered (10PP vaccine or Synflorix™)

Notes
[31] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Cohort 1 subjects participated in Step 1 . Cohort 2 subjects participated in Step 2. Please, refer to the title of the endpoint: Statistics are presented only for the groups belonging to the concerned Cohort/Step and the vaccination schedule.

End point values	10PP-HD 2+1d Group	Synflorix 2+1d Group
Number of subjects analysed	190	190
Units: EL.U/mL
geometric mean (confidence interval 95%)
Anti-PD 1 Mth post dose 2 (N=187, 187)	990.9 (869.3 to 1129.5)	1126.7 (999.4 to 1270.2)
Anti-PD 5 Mth post dose 2 (N=188, 187)	281.3 (247.5 to 319.7)	313 (276.2 to 354.7)
Anti-PD 3 Mth post dose 3 (N=190, 190)	534.8 (468.9 to 610)	664.9 (580.1 to 762.2)

No statistical analyses for this end point

Secondary: Antibody concentrations against vaccine serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F – For Cohort 2/Step 2 subjects who received the 3+0 Schedule

Top of page

End point title

Antibody concentrations against vaccine serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F – For Cohort 2/Step 2 subjects who received the 3+0 Schedule ^[32]

End point description

End point type

Secondary

End point timeframe

At 1, 5 and 8 months (Mth) post-Dose 3 of pneumococcal vaccine administered (10PP vaccine, Synflorix™ or Prevnar 13™)

Notes
[32] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Cohort 1 subjects participated in Step 1 . Cohort 2 subjects participated in Step 2. Please, refer to the title of the endpoint: Statistics are presented only for the groups belonging to the concerned Cohort/Step and the vaccination schedule.

End point values	10PP-LD 3+0d Group	10PP-HD 3+0d Group	Synflorix 3+0d Group	Prevnar13 3+0d Group
Number of subjects analysed	191	195	196	195
Units: µg/mL
geometric mean (confidence interval 95%)
Anti-1 1 Mth post dose 3 (N=191, 194, 193, 193)	3.58 (3.17 to 4.03)	3.2 (2.82 to 3.63)	3.38 (2.98 to 3.83)	5.51 (4.92 to 6.17)
Anti-1 5 Mth post dose 3 (N=190, 192, 195, 189)	0.67 (0.59 to 0.76)	0.55 (0.49 to 0.63)	0.62 (0.55 to 0.71)	1.16 (1.05 to 1.29)
Anti-1 8 Mth post dose 3 (N=189, 189, 194, 187)	0.4 (0.35 to 0.45)	0.35 (0.31 to 0.4)	0.4 (0.35 to 0.46)	0.83 (0.73 to 0.93)
Anti-4 1 Mth post dose 3 (N=191, 195, 195, 192)	3.89 (3.43 to 4.41)	3.15 (2.75 to 3.6)	3.75 (3.29 to 4.28)	6.25 (5.63 to 6.93)
Anti-4 5 Mth post dose 3 (N=191, 192, 194, 190)	1.19 (1.06 to 1.34)	1.04 (0.93 to 1.16)	1.14 (1 to 1.29)	1.06 (0.94 to 1.19)
Anti-4 8 Mth post dose 3 (N=189, 190, 195, 188)	0.7 (0.62 to 0.79)	0.59 (0.52 to 0.68)	0.66 (0.58 to 0.76)	0.54 (0.48 to 0.61)
Anti-5 1 Mth post dose 3 (N=186, 193, 187, 190)	5.17 (4.54 to 5.88)	4.83 (4.21 to 5.54)	5.3 (4.66 to 6.02)	7.02 (6.14 to 8.02)
Anti-5 5 Mth post dose 3 (N=190, 192, 194, 190)	1.37 (1.21 to 1.55)	1.25 (1.1 to 1.43)	1.33 (1.17 to 1.51)	1.79 (1.59 to 2.02)
Anti-5 8 Mth post dose 3 (N=189, 187, 194, 187)	0.73 (0.65 to 0.83)	0.68 (0.59 to 0.79)	0.69 (0.6 to 0.79)	1.12 (0.99 to 1.27)
Anti-6B 1 Mth post dose 3 (N=190, 194, 192, 191)	0.91 (0.74 to 1.12)	0.69 (0.56 to 0.86)	1 (0.8 to 1.25)	1.35 (1.11 to 1.65)
Anti-6B 5 Mth post dose 3 (N=190, 190, 194, 189)	1.1 (0.94 to 1.29)	0.86 (0.73 to 1.01)	1.24 (1.06 to 1.44)	0.38 (0.33 to 0.44)
Anti-6B 8 Mth post dose 3 (N=189, 189, 195, 188)	0.87 (0.75 to 1)	0.73 (0.62 to 0.86)	0.96 (0.83 to 1.11)	0.29 (0.26 to 0.34)
Anti-7F 1 Mth post dose 3 (N=190, 194, 195, 195)	4.63 (4.1 to 5.22)	4.1 (3.62 to 4.63)	4.29 (3.77 to 4.88)	5.53 (4.96 to 6.17)
Anti-7F 5 Mth post dose 3 (N=191, 192, 195, 190)	2.24 (2.01 to 2.5)	1.84 (1.63 to 2.08)	2.19 (1.95 to 2.47)	2.21 (1.99 to 2.45)
Anti-7F 8 Mth post dose 3 (N=189, 190, 195, 188)	1.54 (1.38 to 1.72)	1.31 (1.15 to 1.5)	1.57 (1.39 to 1.78)	1.65 (1.49 to 1.82)
Anti-9V 1 Mth post dose 3 (N=188, 194, 196, 194)	3.23 (2.83 to 3.68)	3.25 (2.83 to 3.72)	3.26 (2.82 to 3.78)	4.02 (3.45 to 4.69)
Anti-9V 5 Mth post dose 3 (N=191, 192, 193, 189)	1.35 (1.2 to 1.53)	1.15 (1.02 to 1.3)	1.33 (1.17 to 1.52)	0.83 (0.72 to 0.95)
Anti-9V 8 Mth post dose 3 (N=189, 189, 195, 188)	1.09 (0.95 to 1.25)	0.87 (0.77 to 1)	1.08 (0.95 to 1.23)	0.63 (0.55 to 0.73)
Anti-14 1 Mth post dose 3 (N=191, 193, 192, 194)	4.36 (3.7 to 5.13)	4.11 (3.49 to 4.85)	4.15 (3.52 to 4.89)	4.66 (3.93 to 5.52)
Anti-14 5 Mth post dose 3 (N=190, 192, 194, 189)	2.15 (1.84 to 2.5)	1.86 (1.56 to 2.22)	2.13 (1.77 to 2.56)	3.43 (2.89 to 4.06)
Anti-14 8 Mth post dose 3 (N=189, 190, 195, 188)	1.38 (1.18 to 1.61)	1.37 (1.15 to 1.63)	1.42 (1.18 to 1.71)	2.47 (2.1 to 2.92)
Anti-18C 1 Mth post dose 3 (N=186, 194, 189, 193)	15.88 (13.8 to 18.26)	14.84 (12.88 to 17.09)	15.66 (13.52 to 18.14)	5.78 (5.03 to 6.64)
Anti-18C 5 Mth post dose 3 (N=191, 192, 195, 190)	4.09 (3.54 to 4.71)	3.52 (3.06 to 4.05)	4.17 (3.6 to 4.83)	0.95 (0.84 to 1.06)
Anti-18C 8 Mth post dose 3 (N=189, 190, 195, 188)	2.18 (1.9 to 2.51)	1.82 (1.58 to 2.1)	2.24 (1.95 to 2.58)	0.66 (0.58 to 0.75)
Anti-19F 1 Mth post dose 3 (N=189, 193, 193, 193)	9.47 (8.08 to 11.09)	9.36 (8.04 to 10.91)	10.04 (8.54 to 11.8)	5.99 (5.4 to 6.64)
Anti-19F 5 Mth post dose 3 (N=190, 191, 195, 188)	2.65 (2.29 to 3.07)	2.34 (2.03 to 2.71)	3.11 (2.67 to 3.62)	0.96 (0.83 to 1.11)
Anti-19F 8 Mth post dose 3 (N=189, 188, 194, 187)	1.65 (1.4 to 1.93)	1.45 (1.22 to 1.72)	1.99 (1.68 to 2.35)	0.55 (0.46 to 0.66)
Anti-23F 1 Mth post dose 3 (N=185, 194, 189, 192)	1.18 (0.98 to 1.42)	1.14 (0.95 to 1.38)	1.22 (0.99 to 1.51)	2.92 (2.47 to 3.44)
Anti-23F 5 Mth post dose 3 (N=191, 192, 195, 190)	0.78 (0.66 to 0.93)	0.77 (0.66 to 0.89)	0.9 (0.77 to 1.06)	0.47 (0.4 to 0.57)
Anti-23F 8 Mth post dose 3 (N=189, 190, 195, 188)	0.62 (0.53 to 0.73)	0.59 (0.49 to 0.7)	0.68 (0.58 to 0.79)	0.39 (0.31 to 0.48)

No statistical analyses for this end point

Secondary: Antibody concentrations against vaccine serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F – For Cohort 2/Step 2 subjects who received the 2+1 Schedule

Top of page

End point title

Antibody concentrations against vaccine serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F – For Cohort 2/Step 2 subjects who received the 2+1 Schedule ^[33]

End point description

End point type

Secondary

End point timeframe

At 1 and 5 months (Mth) post-Dose 2, and at 3 months post-Dose 3 of the pneumococcal vaccine administered (10PP vaccine or Synflorix™)

Notes
[33] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Cohort 1 subjects participated in Step 1 . Cohort 2 subjects participated in Step 2. Please, refer to the title of the endpoint: Statistics are presented only for the groups belonging to the concerned Cohort/Step and the vaccination schedule.

End point values	10PP-HD 2+1d Group	Synflorix 2+1d Group
Number of subjects analysed	193	193
Units: µg/mL
geometric mean (confidence interval 95%)
Anti-1 1 Mth post dose 2 (N=192, 191)	2.52 (2.22 to 2.86)	2.41 (2.13 to 2.72)
Anti-1 5 Mth post dose 2 (N=189, 191)	0.44 (0.39 to 0.49)	0.42 (0.37 to 0.48)
Anti-1 3 Mth post dose 3 (N=190, 190)	1.65 (1.43 to 1.9)	1.61 (1.41 to 1.83)
Anti-4 1 Mth post dose 2 (N=192, 193)	2.79 (2.42 to 3.22)	2.67 (2.3 to 3.09)
Anti-4 5 Mth post dose 2 (N=189, 190)	0.79 (0.7 to 0.89)	0.76 (0.67 to 0.86)
Anti-4 3 Mth post dose 3 (N=190, 190)	2.15 (1.91 to 2.42)	1.92 (1.71 to 2.16)
Anti-5 1 Mth post dose 2 (N=188, 186)	3.74 (3.29 to 4.26)	3.4 (2.96 to 3.91)
Anti-5 5 Mth post dose 2 (N=188, 190)	1.07 (0.95 to 1.21)	0.92 (0.81 to 1.04)
Anti-5 3 Mth post dose 3 (N=190, 190)	2.86 (2.53 to 3.23)	2.34 (2.04 to 2.69)
Anti-6B 1 Mth post dose 2 (N=189, 189)	0.51 (0.4 to 0.64)	0.51 (0.41 to 0.64)
Anti-6B 5 Mth post dose 2 (N=186, 189)	0.63 (0.53 to 0.75)	0.67 (0.58 to 0.79)
Anti-6B 3 Mth post dose 3 (N=190, 190)	1.35 (1.17 to 1.56)	1.39 (1.21 to 1.61)
Anti-7F 1 Mth post dose 2 (N=192, 191)	3.29 (2.95 to 3.67)	3.06 (2.68 to 3.49)
Anti-7F 5 Mth post dose 2 (N=189, 191)	1.47 (1.3 to 1.66)	1.48 (1.3 to 1.68)
Anti-7F 3 Mth post dose 3 (N=190, 190)	3.36 (3 to 3.77)	3.4 (3.04 to 3.81)
Anti-9V 1 Mth post dose 2 (N=191, 191)	1.85 (1.6 to 2.14)	1.97 (1.72 to 2.26)
Anti-9V 5 Mth post dose 2 (N=189, 191)	0.85 (0.75 to 0.95)	0.81 (0.72 to 0.91)
Anti-9V 3 Mth post dose 3 (N=190, 190)	2.86 (2.54 to 3.23)	2.67 (2.32 to 3.06)
Anti-14 1 Mth post dose 2 (N=192, 190)	2.39 (2.01 to 2.85)	2.29 (1.92 to 2.72)
Anti-14 5 Mth post dose 2 (N=189, 191)	0.85 (0.7 to 1.03)	0.89 (0.75 to 1.06)
Anti-14 3 Mth post dose 3 (N=190, 189)	2.4 (2.07 to 2.79)	2.42 (2.09 to 2.8)
Anti-18C 1 Mth post dose 2 (N=191, 188)	11.33 (9.39 to 13.68)	10.88 (8.98 to 13.18)
Anti-18C 5 Mth post dose 2 (N=189, 190)	3 (2.54 to 3.53)	3.18 (2.71 to 3.74)
Anti-18C 3 Mth post dose 3 (N=190, 190)	18.38 (15.94 to 21.19)	16.24 (14.11 to 18.69)
Anti-19F 1 Mth post dose 2 (N=193, 192)	7.33 (6.17 to 8.71)	7.85 (6.61 to 9.32)
Anti-19F 5 Mth post dose 2 (N=187, 191)	2.38 (2.07 to 2.74)	2.48 (2.12 to 2.9)
Anti-19F 3 Mth post dose 3 (N=189, 189)	5.99 (5.13 to 7.01)	6.27 (5.36 to 7.32)
Anti-23F 1 Mth post dose 2 (N=189, 189)	0.63 (0.51 to 0.78)	0.67 (0.53 to 0.84)
Anti-23F 5 Mth post dose 2 (N=189, 191)	0.44 (0.37 to 0.52)	0.46 (0.39 to 0.55)
Anti-23F 3 Mth post dose 3 (N=190, 190)	1.46 (1.24 to 1.72)	1.5 (1.27 to 1.76)

No statistical analyses for this end point

Secondary: Antibody concentrations against vaccine serotypes 3, 6A and 19A – For Cohort 2/Step 2 subjects who received the 3+0 Schedule

Top of page

End point title

Antibody concentrations against vaccine serotypes 3, 6A and 19A – For Cohort 2/Step 2 subjects who received the 3+0 Schedule ^[34]

End point description

End point type

Secondary

End point timeframe

At 1, 5 and 8 months (Mth) post-Dose 3 of pneumococcal vaccine administered (10PP vaccine, Synflorix™ or Prevnar 13™)

Notes
[34] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Cohort 1 subjects participated in Step 1 . Cohort 2 subjects participated in Step 2. Please, refer to the title of the endpoint: Statistics are presented only for the groups belonging to the concerned Cohort/Step and the vaccination schedule.

End point values	10PP-LD 3+0d Group	10PP-HD 3+0d Group	Synflorix 3+0d Group	Prevnar13 3+0d Group
Number of subjects analysed	189	192	195	192
Units: µg/mL
geometric mean (confidence interval 95%)
Anti-3 1 Mth post dose 3 (N=184, 192, 186, 192)	0.05 (0.04 to 0.06)	0.05 (0.04 to 0.05)	0.05 (0.04 to 0.06)	4.52 (4.15 to 4.92)
Anti-3 5 Mth post dose 3 (N=189, 192, 191, 188)	0.06 (0.05 to 0.07)	0.06 (0.05 to 0.08)	0.07 (0.06 to 0.09)	0.6 (0.52 to 0.68)
Anti-3 8 Mth post dose 3 (N=188, 190, 195, 187)	0.08 (0.07 to 0.11)	0.09 (0.07 to 0.12)	0.09 (0.07 to 0.11)	0.32 (0.27 to 0.38)
Anti-19A 1 Mth post dose 3 (N=185, 190, 182, 191)	0.24 (0.2 to 0.29)	0.2 (0.17 to 0.24)	0.23 (0.19 to 0.27)	5.27 (4.41 to 6.3)
Anti-19A 5 Mth post dose 3 (N=187, 186, 194, 187)	0.21 (0.17 to 0.25)	0.17 (0.14 to 0.21)	0.24 (0.2 to 0.3)	0.91 (0.76 to 1.08)
Anti-19A 8 Mth post dose 3 (N=184, 185, 192, 185)	0.24 (0.19 to 0.29)	0.21 (0.17 to 0.27)	0.27 (0.22 to 0.34)	0.64 (0.52 to 0.79)

No statistical analyses for this end point

Secondary: Antibody concentrations against vaccine serotypes 3, 6A and 19A – For Cohort 2/Step 2 subjects who received the 2+1 Schedule

Top of page

End point title

Antibody concentrations against vaccine serotypes 3, 6A and 19A – For Cohort 2/Step 2 subjects who received the 2+1 Schedule ^[35]

End point description

End point type

Secondary

End point timeframe

At 1 and 5 months (Mth) post-Dose 2, and at 3 months post-Dose 3 of the pneumococcal vaccine administered (10PP vaccine or Synflorix™)

Notes
[35] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Cohort 1 subjects participated in Step 1 . Cohort 2 subjects participated in Step 2. Please, refer to the title of the endpoint: Statistics are presented only for the groups belonging to the concerned Cohort/Step and the vaccination schedule.

End point values	10PP-HD 2+1d Group	Synflorix 2+1d Group
Number of subjects analysed	190	191
Units: µg/mL
geometric mean (confidence interval 95%)
Anti-3 1 Mth post dose 2 (N=186, 187)	0.04 (0.04 to 0.05)	0.05 (0.04 to 0.06)
Anti-3 5 Mth post dose 2 (N=187, 191)	0.06 (0.05 to 0.07)	0.07 (0.05 to 0.09)
Anti-3 3 Mth post dose 3 (N=190, 190)	0.07 (0.06 to 0.09)	0.08 (0.06 to 0.1)
Anti-19A 1 Mth post dose 2 (N=187, 186)	0.24 (0.2 to 0.29)	0.25 (0.2 to 0.3)
Anti-19A 5 Mth post dose 2 (N=183, 190)	0.18 (0.15 to 0.22)	0.19 (0.15 to 0.24)
Anti-19A 3 Mth post dose 3 (N=190, 187)	0.56 (0.43 to 0.71)	0.64 (0.5 to 0.81)

No statistical analyses for this end point

Secondary: Titers for opsonophagocytic activity against vaccine serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F – For Cohort 2/Step 2 subjects receiving the 3+0 Schedule

Top of page

End point title

Titers for opsonophagocytic activity against vaccine serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F – For Cohort 2/Step 2 subjects receiving the 3+0 Schedule ^[36]

End point description

The cut-off of the assay was a titer for opsonophagocytic activity higher than or equal to (≥) 8. This outcome concerns subjects enrolled in Cohort 2/Step 2 receiving the 3+0 Schedule.

End point type

Secondary

End point timeframe

At 1, 5 and 8 months (Mth) post-Dose 3 of pneumococcal vaccine administered (10PP vaccine, Synflorix™ or Prevnar 13™)

Notes
[36] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Cohort 1 subjects participated in Step 1 . Cohort 2 subjects participated in Step 2. Please, refer to the title of the endpoint: Statistics are presented only for the groups belonging to the concerned Cohort/Step and the vaccination schedule.

End point values	10PP-LD 3+0d Group	10PP-HD 3+0d Group	Synflorix 3+0d Group	Prevnar13 3+0d Group
Number of subjects analysed	93	96	98	96
Units: Titers
geometric mean (confidence interval 95%)
OPSONO-1 1 Mth post dose 3 (N=93, 96, 98, 96)	136.3 (98.8 to 188)	62.7 (42.8 to 91.9)	109.9 (79.2 to 152.6)	161.4 (116.5 to 223.8)
OPSONO-1 5 Mth post dose 3 (N=93, 95, 94, 90)	14.1 (9.9 to 20)	10.1 (7.4 to 13.8)	11 (7.9 to 15.3)	14.3 (9.9 to 20.4)
OPSONO-1 8 Mth post dose 3 (N=91, 95, 96, 88)	10 (7.3 to 13.6)	8.4 (6.4 to 11)	9.3 (6.9 to 12.5)	12.5 (8.8 to 17.6)
OPSONO-4 1 Mth post dose 3 (N=91, 95, 98, 94)	835 (657.1 to 1061)	784 (633.1 to 970.8)	715.6 (586.5 to 873.2)	1022.7 (839.6 to 1245.7)
OPSONO-4 5 Mth post dose 3 (N=86, 91, 93, 84)	86 (58.5 to 126.4)	48.2 (31.5 to 73.7)	54.7 (37.2 to 80.4)	62.8 (40 to 98.4)
OPSONO-4 8 Mth post dose 3 (N=86, 90, 91, 85)	48.2 (31 to 74.9)	34.3 (21.8 to 53.9)	41.7 (27.4 to 63.7)	41.8 (25.9 to 67.5)
OPSONO-5 1 Mth post dose 3 (N=93, 95, 97, 96)	97.9 (75.5 to 127)	51.4 (37.8 to 70.1)	76.7 (58.5 to 100.6)	91.5 (69.7 to 120.2)
OPSONO-5 5 Mth post dose 3 (N=93, 96, 97, 90)	19.7 (14.9 to 26.1)	13.1 (10 to 17.3)	16.2 (12.1 to 21.5)	17.4 (13.2 to 23)
OPSONO-5 8 Mth post dose 3 (N=92, 95, 98, 89)	9.4 (7.4 to 11.9)	8.3 (6.5 to 10.5)	11.2 (8.7 to 14.2)	10.8 (8.5 to 13.6)
OPSONO-6B 1 Mth post dose 3 (N=93, 95, 96, 96)	827.6 (601.4 to 1138.9)	432.8 (293.1 to 638.8)	814.6 (594.1 to 1116.9)	1317.6 (937.1 to 1852.6)
OPSONO-6B 5 Mth post dose 3 (N=93, 91, 97, 88)	242.4 (158.9 to 369.9)	251.3 (169.1 to 373.4)	324 (227.2 to 461.9)	90.9 (53.3 to 155)
OPSONO-6B 8 Mth post dose 3 (N=90, 88, 97, 83)	146.9 (95.9 to 225.1)	126 (80.4 to 197.4)	233.1 (160.7 to 338.1)	73.7 (43.3 to 125.4)
OPSONO-7F 1 Mth post dose 3 (N=93, 95, 98, 96)	3755.3 (3060.5 to 4607.9)	2993.3 (2440.1 to 3672)	3767.9 (2981.2 to 4762.1)	7241 (5923.2 to 8852.1)
OPSONO-7F 5 Mth post dose 3 (N=93, 96, 97, 90)	2072.1 (1634.8 to 2626.3)	1850.6 (1454.8 to 2354.1)	1710.3 (1329.7 to 2199.9)	3652.1 (2878.1 to 4634.2)
OPSONO-7F 8 Mth post dose 3 (N=92, 95, 98, 89)	2001.5 (1629.3 to 2458.7)	2313 (1851.4 to 2889.8)	2291.2 (1903.9 to 2757.3)	3054.1 (2502.7 to 3727)
OPSONO-9V 1 Mth post dose 3 (N=93, 96, 98, 94)	909.2 (722.3 to 1144.5)	1113.1 (888 to 1395.3)	1044.6 (788.6 to 1383.6)	878.3 (647.7 to 1191)
OPSONO-9V 5 Mth post dose 3 (N=92, 95, 97, 90)	360.3 (253.2 to 512.7)	449.2 (347.2 to 581.3)	320.1 (236.2 to 433.6)	342.8 (240.3 to 489)
OPSONO-9V 8 Mth post dose 3 (N=89, 92, 97, 88)	330.6 (230.2 to 474.9)	436.7 (322.5 to 591.4)	277 (196.1 to 391.4)	308.6 (216.6 to 439.7)
OPSONO-14 1 Mth post dose 3 (N=93, 95, 97, 93)	1176.2 (823.1 to 1680.9)	1169.8 (845.3 to 1618.9)	1139.9 (773.2 to 1680.4)	2504.7 (1665.7 to 3766.3)
OPSONO-14 5 Mth post dose 3 (N=89, 95, 95, 89)	188.9 (129.7 to 275)	181.3 (125.6 to 261.5)	233.4 (160.2 to 340.1)	499.3 (350.5 to 711.1)
OPSONO-14 8 Mth post dose 3 (N=88, 89, 95, 89)	152.9 (103 to 227.1)	186.9 (130.5 to 267.6)	223.1 (159 to 313.2)	371 (257.6 to 534.2)
OPSONO-18C 1 Mth post dose 3 (N=93, 96, 98, 94)	666.2 (542.9 to 817.6)	532 (413.8 to 683.9)	623.6 (493.1 to 788.6)	277.7 (209.9 to 367.5)
OPSONO-18C 5 Mth post dose 3 (N=92, 95, 96, 90)	39.8 (29.4 to 54)	32 (22.9 to 44.6)	44.1 (32.7 to 59.5)	9.1 (7 to 11.8)
OPSONO-18C 8 Mth post dose 3 (N=88, 92, 97, 88)	13.6 (10.2 to 18.1)	11.7 (9 to 15.1)	16.9 (12.8 to 22.4)	6.5 (5 to 8.3)
OPSONO-19F 1 Mth post dose 3 (N=90, 95, 98, 94)	420.3 (307.6 to 574.2)	340.6 (242.7 to 478)	518.3 (389.1 to 690.4)	84.8 (66.1 to 108.9)
OPSONO-19F 5 Mth post dose 3 (N=92, 96, 98, 91)	47.2 (35.3 to 62.9)	30.7 (22.8 to 41.4)	66.9 (49.3 to 90.9)	7.2 (5.4 to 9.5)
OPSONO-19F 8 Mth post dose 3 (N=92, 94, 97, 89)	22 (16.3 to 29.6)	20.3 (14.6 to 28.5)	32.5 (23.6 to 44.7)	7 (5.4 to 9.2)
OPSONO-23F 1 Mth post dose 3 (N=93, 94, 98, 96)	1421.3 (976.4 to 2068.9)	965.1 (622.7 to 1495.8)	1030.2 (693 to 1531.4)	2821.9 (1913.1 to 4162.3)
OPSONO-23F 5 Mth post dose 3 (N=85, 87, 90, 86)	307.4 (183 to 516.3)	387.1 (234.4 to 639.1)	239.5 (140.2 to 409.1)	638.6 (369.2 to 1104.6)
OPSONO-23F 8 Mth post dose 3 (N=87, 81, 89, 83)	306.2 (172.3 to 543.9)	385.9 (221.1 to 673.5)	410.8 (246.7 to 684.2)	650.4 (367.1 to 1152.3)

No statistical analyses for this end point

Secondary: Titers for opsonophagocytic activity against vaccine serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F – For Cohort 2/Step 2 subjects receiving the 2+1 Schedule

Top of page

End point title

Titers for opsonophagocytic activity against vaccine serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F – For Cohort 2/Step 2 subjects receiving the 2+1 Schedule ^[37]

End point description

The cut-off of the assay was a titer for opsonophagocytic activity higher than or equal to (≥) 8. This outcome concerns subjects enrolled in Cohort 2/Step 2 receiving the 2+1 Schedule.

End point type

Secondary

End point timeframe

At 1 and 5 months (Mth) post-Dose 2, and at 3 months post-Dose 3 of the pneumococcal vaccine administered (10PP vaccine or Synflorix™)

Notes
[37] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Cohort 1 subjects participated in Step 1 . Cohort 2 subjects participated in Step 2. Please, refer to the title of the endpoint: Statistics are presented only for the groups belonging to the concerned Cohort/Step and the vaccination schedule.

End point values	10PP-HD 2+1d Group	Synflorix 2+1d Group
Number of subjects analysed	98	97
Units: Titers
geometric mean (confidence interval 95%)
OPSONO-1 1 Mth post dose 2 (N=98, 97)	67.3 (46.5 to 97.4)	58 (40.4 to 83.4)
OPSONO-1 5 Mth post dose 2 (N=95, 95)	7.7 (6 to 9.8)	8.1 (6.1 to 10.7)
OPSONO-1 3 Mth post dose 3 (N=95, 95)	58.8 (38.2 to 90.7)	57.5 (37.8 to 87.5)
OPSONO-4 1 Mth post dose 2 (N=97, 96)	461.9 (377.9 to 564.5)	427.2 (327 to 558)
OPSONO-4 5 Mth post dose 2 (N=92, 90)	27 (18.6 to 39.2)	27.4 (18.6 to 40.4)
OPSONO-4 3 Mth post dose 3 (N=93, 91)	260 (190 to 355.8)	241.1 (170.4 to 341)
OPSONO-5 1 Mth post dose 2 (N=98, 97)	49.1 (37 to 65)	49.1 (36.2 to 66.6)
OPSONO-5 5 Mth post dose 2 (N=95, 95)	11.8 (9.3 to 15.1)	12.6 (9.7 to 16.4)
OPSONO-5 3 Mth post dose 3 (N=96, 95)	58.2 (44 to 77)	47 (34.4 to 64.2)
OPSONO-6B 1 Mth post dose 2 (N=95, 96)	359.8 (240.2 to 539)	331.7 (223.1 to 493.2)
OPSONO-6B 5 Mth post dose 2 (N=91, 91)	159.1 (102 to 248)	111.1 (68.3 to 180.7)
OPSONO-6B 3 Mth post dose 3 (N=94, 89)	214.7 (146.2 to 315.1)	192 (130 to 283.6)
OPSONO-7F 1 Mth post dose 2 (N=98, 96)	2643.3 (2122.6 to 3291.6)	2336.3 (1923.9 to 2837.3)
OPSONO-7F 5 Mth post dose 2 (N=95, 94)	1258.2 (972.6 to 1627.6)	1466.4 (1150.1 to 1869.7)
OPSONO-7F 3 Mth post dose 3 (N=96, 95)	2767.6 (2261.7 to 3386.7)	2963.6 (2379 to 3691.9)
OPSONO-9V 1 Mth post dose 2 (N=98, 96)	783.7 (609 to 1008.5)	763.2 (625.4 to 931.4)
OPSONO-9V 5 Mth post dose 2 (N=91, 94)	241.3 (159 to 366.2)	163.3 (113.8 to 234.3)
OPSONO-9V 3 Mth post dose 3 (N=95, 95)	1044.3 (818.8 to 1332)	712.4 (534.2 to 950)
OPSONO-14 1 Mth post dose 2 (N=98, 96)	349.7 (231.7 to 527.8)	310.5 (200.1 to 481.9)
OPSONO-14 5 Mth post dose 2 (N=89, 91)	54.3 (35.5 to 83)	40.2 (26.6 to 60.8)
OPSONO-14 3 Mth post dose 3 (N=93, 93)	335.9 (257.2 to 438.7)	254.6 (180.4 to 359.4)
OPSONO-18C 1 Mth post dose 2 (N=98, 97)	464.7 (317 to 681.2)	459.7 (330.7 to 639.1)
OPSONO-18C 5 Mth post dose 2 (N=93, 95)	28.4 (20.3 to 39.7)	33.6 (23.5 to 47.8)
OPSONO-18C 3 Mth post dose 3 (N=96, 94)	562.8 (405 to 782)	522 (390 to 698.7)
OPSONO-19F 1 Mth post dose 2 (N=96, 96)	299.3 (213.5 to 419.6)	284.7 (201.1 to 403.1)
OPSONO-19F 5 Mth post dose 2 (N=93, 94)	35.5 (26 to 48.3)	38.7 (27.6 to 54.3)
OPSONO-19F 3 Mth post dose 3 (N=96, 95)	203.6 (140.5 to 295.1)	168.1 (110 to 256.8)
OPSONO-23F 1 Mth post dose 2 (N=94, 95)	539.6 (343.1 to 848.6)	493.9 (308.8 to 789.8)
OPSONO-23F 5 Mth post dose 2 (N=90, 91)	156.5 (88.7 to 276.3)	158.6 (91.1 to 276.1)
OPSONO-23F 3 Mth post dose 3 (N=95, 91)	612.2 (395.6 to 947.4)	835.7 (548.1 to 1274.1)

No statistical analyses for this end point

Secondary: Titers for opsonophagocytic activity against vaccine serotypes 3, 6A and 19A – For Cohort 2/Step 2 subjects receiving the 3+0 Schedule

Top of page

End point title

Titers for opsonophagocytic activity against vaccine serotypes 3, 6A and 19A – For Cohort 2/Step 2 subjects receiving the 3+0 Schedule ^[38]

End point description

The cut-off of the assay was a titer for opsonophagocytic activity higher than or equal to (≥) 8. This outcome concerns subjects enrolled in Cohort 2/Step 2 receiving the 3+0 Schedule. Titers for opsonophagocytic activity against vaccine serotypes 19A will be posted when they become available.

End point type

Secondary

End point timeframe

At 1, 5 and 8 months (Mth) post-Dose 3 of pneumococcal vaccine administered (10PP vaccine, Synflorix™ or Prevnar 13™)

Notes
[38] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Cohort 1 subjects participated in Step 1 . Cohort 2 subjects participated in Step 2. Please, refer to the title of the endpoint: Statistics are presented only for the groups belonging to the concerned Cohort/Step and the vaccination schedule.

End point values	10PP-LD 3+0d Group	10PP-HD 3+0d Group	Synflorix 3+0d Group	Prevnar13 3+0d Group
Number of subjects analysed	92	94	97	96
Units: Titers
geometric mean (confidence interval 95%)
OPSONO-3 1 Mth post dose 3 (N=92, 92, 97, 96)	5.3 (4.3 to 6.4)	4.5 (4 to 5.1)	4.8 (4.2 to 5.5)	98.3 (82.8 to 116.7)
OPSONO-3 5 Mth post dose 3 (N=91, 94, 94, 89)	7.1 (5.6 to 9)	5.5 (4.5 to 6.6)	6.7 (5.3 to 8.5)	15.1 (11 to 20.6)
OPSONO-3 8 Mth post dose 3 (N=86, 91, 95, 87)	8.1 (6.3 to 10.5)	8.3 (6.3 to 11)	7.8 (6.1 to 10.1)	12.3 (9 to 16.7)
OPSONO-6A 1 Mth post dose 3 (N=88, 91, 96, 96)	13.7 (9 to 20.9)	11.8 (8 to 17.4)	11.3 (7.7 to 16.5)	2770 (2216.1 to 3462.4)
OPSONO-6A 5 Mth post dose 3 (N=92, 92, 94, 88)	14.8 (9.5 to 23.2)	12 (8 to 17.9)	20.2 (12.7 to 32)	602 (433.4 to 836.2)
OPSONO-6A 8 Mth post dose 3 (N=86, 86, 88, 87)	14.8 (9.4 to 23.3)	12.4 (8.1 to 19.1)	18.5 (11.7 to 29.3)	260.1 (167.4 to 404.2)

No statistical analyses for this end point

Secondary: Titers for opsonophagocytic activity against vaccine serotypes 3, 6A and 19A – For Cohort 2/Step 2 subjects receiving the 2+1 Schedule

Top of page

End point title

Titers for opsonophagocytic activity against vaccine serotypes 3, 6A and 19A – For Cohort 2/Step 2 subjects receiving the 2+1 Schedule ^[39]

End point description

The cut-off of the assay was a titer for opsonophagocytic activity higher than or equal to (≥) 8. This outcome concerns subjects enrolled in Cohort 2/Step 2 receiving the 2+1 Schedule. Titers for opsonophagocytic activity against vaccine serotypes 19A will be posted when they become available.

End point type

Secondary

End point timeframe

At 1 and 5 months (Mth) post-Dose 2, and at 3 months post-Dose 3 of the pneumococcal vaccine administered (10PP vaccine or Synflorix™)

Notes
[39] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Cohort 1 subjects participated in Step 1 . Cohort 2 subjects participated in Step 2. Please, refer to the title of the endpoint: Statistics are presented only for the groups belonging to the concerned Cohort/Step and the vaccination schedule.

End point values	10PP-HD 2+1d Group	Synflorix 2+1d Group
Number of subjects analysed	96	97
Units: Titers
geometric mean (confidence interval 95%)
OPSONO-3 1 Mth post dose 2 (N=96, 97)	4.7 (4.2 to 5.4)	5.1 (4.2 to 6.1)
OPSONO-3 5 Mth post dose 2 (N=87, 86)	5.9 (4.8 to 7.3)	5.9 (4.6 to 7.6)
OPSONO-3 3 Mth post dose 3 (N=92, 93)	7.4 (5.7 to 9.6)	6.8 (5.4 to 8.4)
OPSONO-6A 1 Mth post dose 2 (N=96, 97)	6.7 (5.1 to 8.8)	6.7 (5.1 to 8.7)
OPSONO-6A 5 Mth post dose 2 (N=93, 95)	12.4 (8.4 to 18.3)	12.2 (8.2 to 18.3)
OPSONO-6A 3 Mth post dose 3 (N=88, 91)	12.6 (8.3 to 19.2)	10 (6.7 to 15)

No statistical analyses for this end point

Secondary: Concentrations of antibodies against diphteria (Anti-D) and tetanus (Anti-T) – For Cohort 2/Step 2 subjects receiving the 3+0 Schedule

Top of page

End point title

Concentrations of antibodies against diphteria (Anti-D) and tetanus (Anti-T) – For Cohort 2/Step 2 subjects receiving the 3+0 Schedule ^[40]

End point description

Seroprotection rate = Anti-D or anti-T antibody concentrations >= 0.1 IU/mL. This outcome concerns subjects enrolled in Cohort 2/Step 2 receiving the 3+0 Schedule.

End point type

Secondary

End point timeframe

At 1 month post-Dose 3 of the pneumococcal vaccine administered (10PP vaccine, Synflorix™ or Prevnar 13™)

Notes
[40] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Cohort 1 subjects participated in Step 1 . Cohort 2 subjects participated in Step 2. Please, refer to the title of the endpoint: Statistics are presented only for the groups belonging to the concerned Cohort/Step and the vaccination schedule.

End point values	10PP-LD 3+0d Group	10PP-HD 3+0d Group	Synflorix 3+0d Group	Prevnar13 3+0d Group
Number of subjects analysed	99	99	98	99
Units: IU/mL
geometric mean (confidence interval 95%)
Anti-D 1 Mth post dose 3	2.499 (2.111 to 2.959)	2.696 (2.381 to 3.053)	2.874 (2.524 to 3.272)	1.531 (1.33 to 1.762)
Anti-T 1 Mth post dose 3	4.977 (4.127 to 6.002)	5.113 (4.294 to 6.089)	4.709 (3.994 to 5.551)	4.047 (3.462 to 4.731)

No statistical analyses for this end point

Secondary: Concentrations of antibodies against diphteria (Anti-D) and tetanus (Anti-T) – For Cohort 2/Step 2 subjects receiving the 2+1 Schedule

Top of page

End point title

Concentrations of antibodies against diphteria (Anti-D) and tetanus (Anti-T) – For Cohort 2/Step 2 subjects receiving the 2+1 Schedule ^[41]

End point description

Seroprotection rate = Anti-D or anti-T antibody concentrations >= 0.1 IU/mL. This outcome concerns subjects enrolled in Cohort 2/Step 2 receiving the 2+1 Schedule.

End point type

Secondary

End point timeframe

At 1 month post-Dose 2 of the pneumococcal vaccine administered (10PP vaccine or Synflorix™)

Notes
[41] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Cohort 1 subjects participated in Step 1 . Cohort 2 subjects participated in Step 2. Please, refer to the title of the endpoint: Statistics are presented only for the groups belonging to the concerned Cohort/Step and the vaccination schedule.

End point values	10PP-HD 2+1d Group	Synflorix 2+1d Group
Number of subjects analysed	95	96
Units: IU/mL
geometric mean (confidence interval 95%)
Anti-D 1 Mth post dose 2	2.591 (2.213 to 3.033)	2.56 (2.207 to 2.969)
Anti-T 1 Mth post dose 2	5.714 (4.816 to 6.781)	4.738 (3.905 to 5.749)

No statistical analyses for this end point

Secondary: Concentrations of antibodies against Bordetella pertussis (Anti-BPT) – For Cohort 2/Step 2 subjects receiving the 3+0 Schedule

Top of page

End point title

Concentrations of antibodies against Bordetella pertussis (Anti-BPT) – For Cohort 2/Step 2 subjects receiving the 3+0 Schedule ^[42]

End point description

Seropositivity rate = Anti-BPT concentrations ≥ 15 EL.U/mL. This outcome concerns subjects enrolled in Cohort 2/Step 2 receiving the 3+0 Schedule.

End point type

Secondary

End point timeframe

At 1 month post-Dose 3 of the pneumococcal vaccine administered (10PP vaccine, Synflorix™ or Prevnar 13™)

Notes
[42] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Cohort 1 subjects participated in Step 1 . Cohort 2 subjects participated in Step 2. Please, refer to the title of the endpoint: Statistics are presented only for the groups belonging to the concerned Cohort/Step and the vaccination schedule.

End point values	10PP-LD 3+0d Group	10PP-HD 3+0d Group	Synflorix 3+0d Group	Prevnar13 3+0d Group
Number of subjects analysed	99	99	98	99
Units: EL.U/mL
geometric mean (confidence interval 95%)
Anti-BPT 1 Mth post dose 3	111.9 (99.4 to 125.8)	110.3 (99.3 to 122.5)	105.8 (94.4 to 118.6)	117 (105 to 130.3)

No statistical analyses for this end point

Secondary: Concentrations of antibodies against Bordetella pertussis (Anti-BPT) – For Cohort 2/Step 2 subjects receiving the 2+1 Schedule

Top of page

End point title

Concentrations of antibodies against Bordetella pertussis (Anti-BPT) – For Cohort 2/Step 2 subjects receiving the 2+1 Schedule ^[43]

End point description

Seropositivity rate = Anti-BPT concentrations ≥ 15 EL.U/mL. This outcome concerns subjects enrolled in Cohort 2/Step 2 receiving the 2+1 Schedule.

End point type

Secondary

End point timeframe

At 1 month post-Dose 2 of the pneumococcal vaccine administered (10PP vaccine or Synflorix™)

Notes
[43] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Cohort 1 subjects participated in Step 1 . Cohort 2 subjects participated in Step 2. Please, refer to the title of the endpoint: Statistics are presented only for the groups belonging to the concerned Cohort/Step and the vaccination schedule.

End point values	10PP-HD 2+1d Group	Synflorix 2+1d Group
Number of subjects analysed	94	96
Units: EL.U/mL
geometric mean (confidence interval 95%)
Anti-BPT 1 Mth post dose 2	123.2 (112 to 135.5)	114.7 (101.3 to 129.9)

No statistical analyses for this end point

Secondary: Concentrations of antibodies against polyribosyl ribitol phosphate (Anti-PRP) – For Cohort 2/Step 2 subjects receiving the 3+0 Schedule

Top of page

End point title

Concentrations of antibodies against polyribosyl ribitol phosphate (Anti-PRP) – For Cohort 2/Step 2 subjects receiving the 3+0 Schedule ^[44]

End point description

Seroprotection rate = Anti-PRP antibody concentrations >= 0.15 µg/mL. This outcome concerns subjects enrolled in Cohort 2/Step 2 receiving the 3+0 Schedule.

End point type

Secondary

End point timeframe

At 1 month post-Dose 3 of the pneumococcal vaccine administered (10PP vaccine, Synflorix™ or Prevnar 13™)

Notes
[44] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Cohort 1 subjects participated in Step 1 . Cohort 2 subjects participated in Step 2. Please, refer to the title of the endpoint: Statistics are presented only for the groups belonging to the concerned Cohort/Step and the vaccination schedule.

End point values	10PP-LD 3+0d Group	10PP-HD 3+0d Group	Synflorix 3+0d Group	Prevnar13 3+0d Group
Number of subjects analysed	99	99	98	99
Units: µg/mL
geometric mean (confidence interval 95%)
Anti-PRP 1 Mth post dose 3	23.381 (19.326 to 28.287)	19.397 (15.319 to 24.561)	19.239 (15.085 to 24.537)	18.981 (15.244 to 23.635)

No statistical analyses for this end point

Secondary: Concentrations of antibodies against polyribosyl ribitol phosphate (Anti-PRP) – For Cohort 2/Step 2 subjects receiving the 2+1 Schedule

Top of page

End point title

Concentrations of antibodies against polyribosyl ribitol phosphate (Anti-PRP) – For Cohort 2/Step 2 subjects receiving the 2+1 Schedule ^[45]

End point description

Seroprotection rate = Anti-PRP antibody concentrations >= 0.15 µg/mL. This outcome concerns subjects enrolled in Cohort 2/Step 2 receiving the 2+1 Schedule.

End point type

Secondary

End point timeframe

At 1 month post-Dose 2 of the pneumococcal vaccine administered (10PP vaccine or Synflorix™)

Notes
[45] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Cohort 1 subjects participated in Step 1 . Cohort 2 subjects participated in Step 2. Please, refer to the title of the endpoint: Statistics are presented only for the groups belonging to the concerned Cohort/Step and the vaccination schedule.

End point values	10PP-HD 2+1d Group	Synflorix 2+1d Group
Number of subjects analysed	95	96
Units: µg/mL
geometric mean (confidence interval 95%)
Anti-PRP 1 Mth post dose 2	21.274 (17.909 to 25.272)	21.15 (17.427 to 25.669)

No statistical analyses for this end point

Secondary: Concentrations of antibodies against hepatitis B surface antigens (Anti-HBs) – For Cohort 2/Step 2 subjects receiving the 3+0 Schedule

Top of page

End point title

Concentrations of antibodies against hepatitis B surface antigens (Anti-HBs) – For Cohort 2/Step 2 subjects receiving the 3+0 Schedule ^[46]

End point description

Seroprotection rate = Anti-HB antibody concentrations >= 10 mIU/mL. This outcome concerns subjects enrolled in Cohort 2/Step 2 receiving the 3+0 Schedule.

End point type

Secondary

End point timeframe

At 1 month post-Dose 3 of the pneumococcal vaccine administered (10PP vaccine, Synflorix™ or Prevnar 13™)

Notes
[46] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Cohort 1 subjects participated in Step 1 . Cohort 2 subjects participated in Step 2. Please, refer to the title of the endpoint: Statistics are presented only for the groups belonging to the concerned Cohort/Step and the vaccination schedule.

End point values	10PP-LD 3+0d Group	10PP-HD 3+0d Group	Synflorix 3+0d Group	Prevnar13 3+0d Group
Number of subjects analysed	94	93	91	89
Units: mIU/mL
geometric mean (confidence interval 95%)
Anti-HBs 1 Mth post dose 3	1235.8 (946.9 to 1612.9)	1165.8 (910.7 to 1492.3)	990.1 (757.6 to 1294)	1206.6 (946.2 to 1538.7)

No statistical analyses for this end point

Secondary: Concentrations of antibodies against hepatitis B surface antigens (Anti-HBs) – For Cohort 2/Step 2 subjects receiving the 2+1 Schedule

Top of page

End point title

Concentrations of antibodies against hepatitis B surface antigens (Anti-HBs) – For Cohort 2/Step 2 subjects receiving the 2+1 Schedule ^[47]

End point description

Seroprotection rate = Anti-HB antibody concentrations >= 10 mIU/mL. This outcome concerns subjects enrolled in Cohort 2/Step 2 receiving the 2+1 Schedule.

End point type

Secondary

End point timeframe

At 1 month post-Dose 2 of the pneumococcal vaccine administered (10PP vaccine or Synflorix™)

Notes
[47] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Cohort 1 subjects participated in Step 1 . Cohort 2 subjects participated in Step 2. Please, refer to the title of the endpoint: Statistics are presented only for the groups belonging to the concerned Cohort/Step and the vaccination schedule.

End point values	10PP-HD 2+1d Group	Synflorix 2+1d Group
Number of subjects analysed	89	88
Units: mIU/mL
geometric mean (confidence interval 95%)
Anti-HBs 1 Mth post dose 2	1318.5 (1062.5 to 1636.3)	976.5 (724.2 to 1316.8)

No statistical analyses for this end point

Secondary: Antibody titers against poliovirus 1, 2 and 3 (Anti-Polio, Anti-Polio 2 and Anti-Polio 3) – For Cohort 2/Step 2 subjects receiving the 3+0 Schedule

Top of page

End point title

Antibody titers against poliovirus 1, 2 and 3 (Anti-Polio, Anti-Polio 2 and Anti-Polio 3) – For Cohort 2/Step 2 subjects receiving the 3+0 Schedule ^[48]

End point description

Seroprotection rate = Anti-Polio titres >= 8. This outcome concerns subjects enrolled in Cohort 2/Step 2 receiving the 3+0 Schedule.

End point type

Secondary

End point timeframe

At 1 month post-Dose 3 of the pneumococcal vaccine administered (10PP vaccine, Synflorix™ or Prevnar 13™)

Notes
[48] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Cohort 1 subjects participated in Step 1 . Cohort 2 subjects participated in Step 2. Please, refer to the title of the endpoint: Statistics are presented only for the groups belonging to the concerned Cohort/Step and the vaccination schedule.

End point values	10PP-LD 3+0d Group	10PP-HD 3+0d Group	Synflorix 3+0d Group	Prevnar13 3+0d Group
Number of subjects analysed	97	92	91	94
Units: Titers
geometric mean (confidence interval 95%)
Anti-Polio 1- 1 Mth post dose 3 (N= 97;92;91;94)	413.2 (287 to 594.9)	314.8 (202.7 to 488.7)	447.9 (278.5 to 720.1)	398.3 (256.6 to 618.3)
Anti-Polio 2- 1 Mth post dose 3 (N= 76;78;76;73)	545.8 (371.6 to 801.6)	619.5 (462 to 830.7)	514.2 (353.8 to 747.2)	536.9 (400.6 to 719.6)
Anti-Polio 3- 1 Mth post dose 3 (N= 80;88;82;84)	135.4 (91.5 to 200.5)	166 (124.5 to 221.5)	110.1 (72.5 to 167.2)	191.8 (129.4 to 284.4)

No statistical analyses for this end point

Secondary: Antibody titers against poliovirus 1, 2 and 3 (Anti-Polio, Anti-Polio 2 and Anti-Polio 3) – For Cohort 2/Step 2 subjects receiving the 2+1 Schedule

Top of page

End point title

Antibody titers against poliovirus 1, 2 and 3 (Anti-Polio, Anti-Polio 2 and Anti-Polio 3) – For Cohort 2/Step 2 subjects receiving the 2+1 Schedule ^[49]

End point description

Seroprotection rate = Anti-Polio titres >= 8. This outcome concerns subjects enrolled in Cohort 2/Step 2 receiving the 2+1 Schedule.

End point type

Secondary

End point timeframe

At 1 month post-Dose 2 of the pneumococcal vaccine administered (10PP vaccine or Synflorix™)

Notes
[49] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Cohort 1 subjects participated in Step 1 . Cohort 2 subjects participated in Step 2. Please, refer to the title of the endpoint: Statistics are presented only for the groups belonging to the concerned Cohort/Step and the vaccination schedule.

End point values	10PP-HD 2+1d Group	Synflorix 2+1d Group
Number of subjects analysed	87	93
Units: Titers
geometric mean (confidence interval 95%)
Anti-Polio 1 - 1 Mth post dose 2 (N=87;93)	330.3 (208.6 to 523)	415.6 (286.7 to 602.6)
Anti-Polio 2 - 1 Mth post dose 2 (N=75;82)	486.7 (319.7 to 741.1)	702.9 (529.6 to 932.8)
Anti-Polio 3 - 1 Mth post dose 2 (N=75;80)	106.9 (71.8 to 159.1)	181.1 (131.7 to 249)

No statistical analyses for this end point

Secondary: Concentrations of antibodies against measles (Anti-Measles) - For Cohort 2/Step 2 subjects receiving the 3+0 Schedule

Top of page

End point title

Concentrations of antibodies against measles (Anti-Measles) - For Cohort 2/Step 2 subjects receiving the 3+0 Schedule ^[50]

End point description

Seroprotection rate = Anti-Measle antibody concentrations >= 150 mIU/mL. This outcome concerns subjects enrolled in Cohort 2/Step 2 receiving the 3+0 Schedule.

End point type

Secondary

End point timeframe

At 3 months (Mth) post-vaccination with Stamaril™/M-Vac™

Notes
[50] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Cohort 1 subjects participated in Step 1 . Cohort 2 subjects participated in Step 2. Please, refer to the title of the endpoint: Statistics are presented only for the groups belonging to the concerned Cohort/Step and the vaccination schedule.

End point values	10PP-LD 3+0d Group	10PP-HD 3+0d Group	Synflorix 3+0d Group	Prevnar13 3+0d Group
Number of subjects analysed	90	95	96	86
Units: mIU/mL
geometric mean (confidence interval 95%)
Anti-Measle	329.2 (272.6 to 397.5)	298.6 (254.9 to 349.8)	295.8 (237.2 to 368.8)	274.1 (227.7 to 330)

No statistical analyses for this end point

Secondary: Concentrations of antibodies against measles (Anti-Measles) - For Cohort 2/Step 2 subjects receiving the 2+1 Schedule

Top of page

End point title

Concentrations of antibodies against measles (Anti-Measles) - For Cohort 2/Step 2 subjects receiving the 2+1 Schedule ^[51]

End point description

Seroprotection rate = Anti-Measle antibody concentrations >= 150 mIU/mL. This outcome concerns subjects enrolled in Cohort 2/Step 2 receiving the 2+1 Schedule.

End point type

Secondary

End point timeframe

At 3 months (Mth) post-vaccination with Stamaril™/M-Vac™

Notes
[51] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Cohort 1 subjects participated in Step 1 . Cohort 2 subjects participated in Step 2. Please, refer to the title of the endpoint: Statistics are presented only for the groups belonging to the concerned Cohort/Step and the vaccination schedule.

End point values	10PP-HD 2+1d Group	Synflorix 2+1d Group
Number of subjects analysed	96	94
Units: mIU/mL
geometric mean (confidence interval 95%)
Anti-Measle	284.5 (240.9 to 336)	305.9 (256.5 to 364.8)

No statistical analyses for this end point

Secondary: Titers of antibodies against yellow fever (Anti-YF) – For Cohort 2/Step 2 subjects receiving the 3+0 Schedule

Top of page

End point title

Titers of antibodies against yellow fever (Anti-YF) – For Cohort 2/Step 2 subjects receiving the 3+0 Schedule ^[52]

End point description

Seroprotection rate = Anti-yellow fever antibody titers >= 10. This outcome concerns subjects enrolled in Cohort 2/Step 2 receiving the 3+0 Schedule.

End point type

Secondary

End point timeframe

At 3 months (Mth) post-vaccination with Stamaril™/M-Vac™

Notes
[52] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Cohort 1 subjects participated in Step 1 . Cohort 2 subjects participated in Step 2. Please, refer to the title of the endpoint: Statistics are presented only for the groups belonging to the concerned Cohort/Step and the vaccination schedule.

End point values	10PP-LD 3+0d Group	10PP-HD 3+0d Group	Synflorix 3+0d Group	Prevnar13 3+0d Group
Number of subjects analysed	97	95	97	98
Units: Titers
geometric mean (confidence interval 95%)
Anti-yellow fever	334 (250.6 to 445.1)	264.7 (201 to 348.5)	379.9 (293.2 to 492.2)	306.7 (242.9 to 387.3)

No statistical analyses for this end point

Secondary: Titers of antibodies against yellow fever (Anti-YF) – For Cohort 2/Step 2 subjects receiving the 2+1 Schedule

Top of page

End point title

Titers of antibodies against yellow fever (Anti-YF) – For Cohort 2/Step 2 subjects receiving the 2+1 Schedule ^[53]

End point description

Seroprotection rate = Anti-yellow fever antibody titers >= 10. This outcome concerns subjects enrolled in Cohort 2/Step 2 receiving the 2+1 Schedule.

End point type

Secondary

End point timeframe

At 3 months (Mth) post-vaccination with Stamaril™/M-Vac™

Notes
[53] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Cohort 1 subjects participated in Step 1 . Cohort 2 subjects participated in Step 2. Please, refer to the title of the endpoint: Statistics are presented only for the groups belonging to the concerned Cohort/Step and the vaccination schedule.

End point values	10PP-HD 2+1d Group	Synflorix 2+1d Group
Number of subjects analysed	94	95
Units: Titers
geometric mean (confidence interval 95%)
Anti-yellow fever	342 (252.2 to 463.7)	239 (176 to 324.5)

No statistical analyses for this end point

Secondary: Number of subjects with any unsolicited adverse events (AEs) – For Step 2/Cohort 2 subjects receiving the 2+1 Schedule

Top of page

End point title

Number of subjects with any unsolicited adverse events (AEs) – For Step 2/Cohort 2 subjects receiving the 2+1 Schedule ^[54]

End point description

An unsolicited AE is any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. For marketed medicinal products, this also includes failure to produce expected benefits (i.e. lack of efficacy), abuse or misuse. Any = Occurrence of an unsolicited AE, regardless of intensity or relationship to vaccination. This outcome concerns Step 2/Cohort 2 subjects receiving the 2+1 Schedule.

End point type

Secondary

End point timeframe

Within the 31-day (Days 0-30) period post vaccination with Dose 3 of pneumococcal vaccine (10PP vaccine or Synflorix™)

Notes
[54] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Cohort 1 subjects participated in Step 1 . Cohort 2 subjects participated in Step 2. Please, refer to the title of the endpoint: Statistics are presented only for the groups belonging to the concerned Cohort/Step and the vaccination schedule.

End point values	10PP-HD 2+1d Group	Synflorix 2+1d Group
Number of subjects analysed	191	195
Units: Subjects
Any AE(s)	7	2

No statistical analyses for this end point

Secondary: Number of subjects with any serious adverse events (SAEs) – For Step 2/Cohort 2 subjects receiving the 3+0 Schedule

Top of page

End point title

Number of subjects with any serious adverse events (SAEs) – For Step 2/Cohort 2 subjects receiving the 3+0 Schedule ^[55]

End point description

SAEs assessed include medical occurrences that result in death, are life-threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity. These should also be considered serious: invasive or malignant cancers, intensive treatment in an emergency room or at home for allergic bronchospasm, blood dyscrasias or convulsions that do not result in hospitalization. Any = Occurrence of an SAE, regardless of relationship to vaccination. This outcome concerns subjects enrolled in Cohort 2/Step 2 receiving the 3+0 Schedule.

End point type

Secondary

End point timeframe

From Day 0 to Month 10

Notes
[55] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Cohort 1 subjects participated in Step 1 . Cohort 2 subjects participated in Step 2. Please, refer to the title of the endpoint: Statistics are presented only for the groups belonging to the concerned Cohort/Step and the vaccination schedule.

End point values	10PP-LD 3+0d Group	10PP-HD 3+0d Group	Synflorix 3+0d Group	Prevnar13 3+0d Group
Number of subjects analysed	200	200	200	200
Units: Subjects
Any SAE(s)	1	4	3	2

No statistical analyses for this end point

Secondary: Number of subjects with any serious adverse events (SAEs) – For Step 2/Cohort 2 subjects receiving the 2+1 Schedule

Top of page

End point title

Number of subjects with any serious adverse events (SAEs) – For Step 2/Cohort 2 subjects receiving the 2+1 Schedule ^[56]

End point description

End point type

Secondary

End point timeframe

From Day 0 to Month 10

Notes
[56] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Cohort 1 subjects participated in Step 1 . Cohort 2 subjects participated in Step 2. Please, refer to the title of the endpoint: Statistics are presented only for the groups belonging to the concerned Cohort/Step and the vaccination schedule.

End point values	10PP-HD 2+1d Group	Synflorix 2+1d Group
Number of subjects analysed	200	200
Units: Subjects
Any SAE(s)	4	5

No statistical analyses for this end point

Secondary: Number of subjects with Streptococcus pneumoniae in the nasopharynx – For Cohort 2/Step 2 subjects receiving the 3+0 Schedule

Top of page

End point title

Number of subjects with Streptococcus pneumoniae in the nasopharynx – For Cohort 2/Step 2 subjects receiving the 3+0 Schedule ^[57]

End point description

Numbers of subjects with positive nasopharyngeal sample were calculated per group, at each swab time point. This outcome concerns subjects enrolled in Cohort 2/Step 2 receiving the 3+0 Schedule.

End point type

Secondary

End point timeframe

At 1, 5 and 8 months (Mth) post-Dose 3 of pneumococcal vaccine administered (10PP vaccine, Synflorix™ or Prevnar 13™)

Notes
[57] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Cohort 1 subjects participated in Step 1 . Cohort 2 subjects participated in Step 2. Please, refer to the title of the endpoint: Statistics are presented only for the groups belonging to the concerned Cohort/Step and the vaccination schedule.

End point values	10PP-LD 3+0d Group	10PP-HD 3+0d Group	Synflorix 3+0d Group	Prevnar13 3+0d Group
Number of subjects analysed	193	194	196	196
Units: Subjects
At 1 Mth post dose 3 (N=193;194;196;196)	165	158	166	155
At 5 Mth post dose 3 (N=193;192;194;193)	166	161	176	168
At 8 Mth post dose 3 (N=189;189;194;191)	174	166	174	171

No statistical analyses for this end point

Secondary: Number of subjects with Streptococcus pneumoniae (any) in the nasopharynx – For Cohort 2/Step 2 subjects receiving the 2+1 Schedule

Top of page

End point title

Number of subjects with Streptococcus pneumoniae (any) in the nasopharynx – For Cohort 2/Step 2 subjects receiving the 2+1 Schedule ^[58]

End point description

Numbers of subjects with positive nasopharyngeal sample were calculated per group, at each swab time point. This outcome concerns subjects enrolled in Cohort 2/Step 2 receiving the 2+1 Schedule.

End point type

Secondary

End point timeframe

At 1 and 5 months (Mth) post-Dose 2, and at 3 months post-Dose 3 of the pneumococcal vaccine administered (10PP vaccine or Synflorix™)

Notes
[58] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Cohort 1 subjects participated in Step 1 . Cohort 2 subjects participated in Step 2. Please, refer to the title of the endpoint: Statistics are presented only for the groups belonging to the concerned Cohort/Step and the vaccination schedule.

End point values	10PP-HD 2+1d Group	Synflorix 2+1d Group
Number of subjects analysed	197	197
Units: Subjects
At 1 Mth post-dose 2 N=(197;197)	159	162
At 5 Mth post-dose 2 N=(189;194)	164	173
At 3 Mths post-dose 3 N=(190;193)	178	176

No statistical analyses for this end point

Secondary: Number of subjects with Streptococcus pneumoniae (10Pn-PD-DiT vaccine serotypes) in the nasopharynx – For Cohort 2/Step 2 subjects receiving the 3+0 Schedule

Top of page

End point title

Number of subjects with Streptococcus pneumoniae (10Pn-PD-DiT vaccine serotypes) in the nasopharynx – For Cohort 2/Step 2 subjects receiving the 3+0 Schedule ^[59]

End point description

Numbers of subjects with positive nasopharyngeal sample were calculated per group, at each swab time point. A Streptococcus. Pneumoniae (S. pn). vaccine pneumococcal serotype was defined as any of the pneumococcal S. pn. vaccine serotypes, e. a. serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F. This outcome concerns subjects enrolled in Cohort 2/Step 2 receiving the 3+0 Schedule.

End point type

Secondary

End point timeframe

At 1, 5 and 8 months (Mth) post-Dose 3 of pneumococcal vaccine administered (10PP vaccine, Synflorix™ or Prevnar 13™)

Notes
[59] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Cohort 1 subjects participated in Step 1 . Cohort 2 subjects participated in Step 2. Please, refer to the title of the endpoint: Statistics are presented only for the groups belonging to the concerned Cohort/Step and the vaccination schedule.

End point values	10PP-LD 3+0d Group	10PP-HD 3+0d Group	Synflorix 3+0d Group	Prevnar13 3+0d Group
Number of subjects analysed	193	194	196	196
Units: Subjects
At 1 Mth post dose 3 (N=193;194;196;196)	24	31	34	29
At 5 Mth post dose 3 (N=193;192;194;193)	25	23	28	30
At 8 Mth post dose 3 (N=189;189;194;191)	24	15	16	21

No statistical analyses for this end point

Secondary: Number of subjects with Streptococcus pneumoniae (10Pn-PD-DiT vaccine serotypes) in the nasopharynx – For Cohort 2/Step 2 subjects receiving the 2+1 Schedule

Top of page

End point title

Number of subjects with Streptococcus pneumoniae (10Pn-PD-DiT vaccine serotypes) in the nasopharynx – For Cohort 2/Step 2 subjects receiving the 2+1 Schedule ^[60]

End point description

End point type

Secondary

End point timeframe

At 1 and 5 months (Mth) post-Dose 2, and at 3 months post-Dose 3 of the pneumococcal vaccine administered (10PP vaccine or Synflorix™)

Notes
[60] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Cohort 1 subjects participated in Step 1 . Cohort 2 subjects participated in Step 2. Please, refer to the title of the endpoint: Statistics are presented only for the groups belonging to the concerned Cohort/Step and the vaccination schedule.

End point values	10PP-HD 2+1d Group	Synflorix 2+1d Group
Number of subjects analysed	197	197
Units: Subjects
At 1 Mth post-dose 2 N=(197;197)	27	24
At 5 Mth post-dose 2 N=(189;194)	24	23
At 3 Mths post-dose 3 N=(190;193)	18	19

No statistical analyses for this end point

Secondary: Number of subjects with Streptococcus pneumoniae (Synflorix related serotypes) in the nasopharynx – For Cohort 2/Step 2 subjects receiving the 3+0 Schedule

Top of page

End point title

Number of subjects with Streptococcus pneumoniae (Synflorix related serotypes) in the nasopharynx – For Cohort 2/Step 2 subjects receiving the 3+0 Schedule ^[61]

End point description

Related serotype = any serotype belonging to the same serogroup as the Synflorix vaccine serotypes, but different from the vaccine serotypes, was considered for the analyses of carriage of S. pneumoniae cross-related serotypes. This outcome concerns subjects enrolled in Cohort 2/Step 2 receiving the 3+0 Schedule.

End point type

Secondary

End point timeframe

At 1, 5 and 8 months (Mth) post-Dose 3 of pneumococcal vaccine administered (10PP vaccine, Synflorix™ or Prevnar 13™)

Notes
[61] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Cohort 1 subjects participated in Step 1 . Cohort 2 subjects participated in Step 2. Please, refer to the title of the endpoint: Statistics are presented only for the groups belonging to the concerned Cohort/Step and the vaccination schedule.

End point values	10PP-LD 3+0d Group	10PP-HD 3+0d Group	Synflorix 3+0d Group	Prevnar13 3+0d Group
Number of subjects analysed	193	194	196	196
Units: Subjects
At 1 Mth post dose 3 (N=193;194;196;196)	57	56	60	48
At 5 Mth post dose 3 (N=193;192;194;193)	54	48	58	46
At 8 Mth post dose 3 (N=189;189;194;191)	45	42	47	42

No statistical analyses for this end point

Secondary: Number of subjects with Streptococcus pneumoniae (Synflorix related serotypes) in the nasopharynx – For Cohort 2/Step 2 subjects receiving the 2+1 Schedule

Top of page

End point title

Number of subjects with Streptococcus pneumoniae (Synflorix related serotypes) in the nasopharynx – For Cohort 2/Step 2 subjects receiving the 2+1 Schedule ^[62]

End point description

End point type

Secondary

End point timeframe

At 1 and 5 months (Mth) post-Dose 2, and at 3 months post-Dose 3 of the pneumococcal vaccine administered (10PP vaccine or Synflorix™)

Notes
[62] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Cohort 1 subjects participated in Step 1 . Cohort 2 subjects participated in Step 2. Please, refer to the title of the endpoint: Statistics are presented only for the groups belonging to the concerned Cohort/Step and the vaccination schedule.

End point values	10PP-HD 2+1d Group	Synflorix 2+1d Group
Number of subjects analysed	197	197
Units: Subjects
At 1 Mth post-dose 2 N=(197;197)	62	50
At 5 Mth post-dose 2 N=(189;194)	45	49
At 3 Mths post-dose 3 N=(190;193)	58	52

No statistical analyses for this end point

Secondary: Number of subjects with Haemophilus influenzae in the nasopharynx – For Cohort 2/Step 2 subjects receiving the 3+0 Schedule

Top of page

End point title

Number of subjects with Haemophilus influenzae in the nasopharynx – For Cohort 2/Step 2 subjects receiving the 3+0 Schedule ^[63]

End point description

This outcome concerns subjects enrolled in Cohort 2/Step 2 receiving the 3+0 Schedule.

End point type

Secondary

End point timeframe

At 1, 5 and 8 months (Mth) post-Dose 3 of pneumococcal vaccine administered (10PP vaccine, Synflorix™ or Prevnar 13™)

Notes
[63] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Cohort 1 subjects participated in Step 1 . Cohort 2 subjects participated in Step 2. Please, refer to the title of the endpoint: Statistics are presented only for the groups belonging to the concerned Cohort/Step and the vaccination schedule.

End point values	10PP-LD 3+0d Group	10PP-HD 3+0d Group	Synflorix 3+0d Group	Prevnar13 3+0d Group
Number of subjects analysed	193	194	195	196
Units: Subjects
At 1 Mth post dose 3 (N=192;194;195;196)	29	33	28	37
At 5 Mth post dose 3 (N=193;192;193;193)	27	28	28	30
At 8 Mth post dose 3 (N=189;189;194;191)	9	13	12	9

No statistical analyses for this end point

Secondary: Number of subjects with Haemophilus influenzae in the nasopharynx – For Cohort 2/Step 2 subjects receiving the 2+1 Schedule

Top of page

End point title

Number of subjects with Haemophilus influenzae in the nasopharynx – For Cohort 2/Step 2 subjects receiving the 2+1 Schedule ^[64]

End point description

This outcome concerns subjects enrolled in Cohort 2/Step 2 receiving the 2+1 Schedule.

End point type

Secondary

End point timeframe

At 1 and 5 months (Mth) post-Dose 2, and at 3 months post-Dose 3 of the pneumococcal vaccine administered (10PP vaccine or Synflorix™)

Notes
[64] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Cohort 1 subjects participated in Step 1 . Cohort 2 subjects participated in Step 2. Please, refer to the title of the endpoint: Statistics are presented only for the groups belonging to the concerned Cohort/Step and the vaccination schedule.

End point values	10PP-HD 2+1d Group	Synflorix 2+1d Group
Number of subjects analysed	197	197
Units: Subjects
At 1 Mth post-dose 2 N=(197;197)	26	23
At 5 Mth post-dose 2 N=(187;194)	20	32
At 3 Mths post-dose 3 N=(190;193)	9	11

No statistical analyses for this end point

Secondary: Number of subjects with Moraxella catarrhalis in the nasopharynx – For Cohort 2/Step 2 subjects receiving the 3+0 Schedule

Top of page

End point title

Number of subjects with Moraxella catarrhalis in the nasopharynx – For Cohort 2/Step 2 subjects receiving the 3+0 Schedule ^[65]

End point description

Positive cultures of other bacterial pathogens [such as S. aureus, Streptococcus pyogenes (Group A streptococci) and Moraxella catarrhalis] identified in the nasopharynx were analyzed. This outcome concerns subjects enrolled in Cohort 2/Step 2 receiving the 3+0 Schedule.

End point type

Secondary

End point timeframe

At 1, 5 and 8 months (Mth) post-Dose 3 of pneumococcal vaccine administered (10PP vaccine, Synflorix™ or Prevnar 13™)

Notes
[65] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Cohort 1 subjects participated in Step 1 . Cohort 2 subjects participated in Step 2. Please, refer to the title of the endpoint: Statistics are presented only for the groups belonging to the concerned Cohort/Step and the vaccination schedule.

End point values	10PP-LD 3+0d Group	10PP-HD 3+0d Group	Synflorix 3+0d Group	Prevnar13 3+0d Group
Number of subjects analysed	193	194	196	196
Units: Subjects
At 1 Mth post dose 3 (N=193;194;196;196)	88	98	104	100
At 5 Mth post dose 3 (N=193;192;194;193)	72	73	78	88
At 8 Mth post dose 3 (N=189;189;194;191)	74	67	70	74

No statistical analyses for this end point

Secondary: Number of subjects with Moraxella catarrhalis in the nasopharynx – For Cohort 2/Step 2 subjects receiving the 2+1 Schedule

Top of page

End point title

Number of subjects with Moraxella catarrhalis in the nasopharynx – For Cohort 2/Step 2 subjects receiving the 2+1 Schedule ^[66]

End point description

End point type

Secondary

End point timeframe

At 1 and 5 months (Mth) post-Dose 2, and at 3 months post-Dose 3 of the pneumococcal vaccine administered (10PP vaccine or Synflorix™)

Notes
[66] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Cohort 1 subjects participated in Step 1 . Cohort 2 subjects participated in Step 2. Please, refer to the title of the endpoint: Statistics are presented only for the groups belonging to the concerned Cohort/Step and the vaccination schedule.

End point values	10PP-HD 2+1d Group	Synflorix 2+1d Group
Number of subjects analysed	197	197
Units: Subjects
At 1 Mth post-dose 2 N=(197;197)	86	93
At 5 Mth post-dose 2 N=(189;194)	73	84
At 3 Mths post-dose 3 N=(190;193)	56	83

No statistical analyses for this end point

Secondary: Number of subjects with Group A Streptococcus in the nasopharynx – For Cohort 2/Step 2 subjects receiving the 3+0 Schedule

Top of page

End point title

Number of subjects with Group A Streptococcus in the nasopharynx – For Cohort 2/Step 2 subjects receiving the 3+0 Schedule ^[67]

End point description

Positive cultures of other bacterial pathogens [such as S. aureus, Streptococcus pyogenes (Group A streptococci) and Moraxella catarrhalis] identified in the nasopharynx were analyzed.This outcome concerns subjects enrolled in Cohort 2/Step 2 receiving the 3+0 Schedule.

End point type

Secondary

End point timeframe

At 1, 5 and 8 months (Mth) post-Dose 3 of pneumococcal vaccine administered (10PP vaccine, Synflorix™ or Prevnar 13™)

Notes
[67] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Cohort 1 subjects participated in Step 1 . Cohort 2 subjects participated in Step 2. Please, refer to the title of the endpoint: Statistics are presented only for the groups belonging to the concerned Cohort/Step and the vaccination schedule.

End point values	10PP-LD 3+0d Group	10PP-HD 3+0d Group	Synflorix 3+0d Group	Prevnar13 3+0d Group
Number of subjects analysed	193	194	196	196
Units: Subjects
At 1 Mth post dose 3 (N=193;194;196;196)	5	4	5	4
At 5 Mth post dose 3 (N=193;192;194;193)	4	3	4	1
At 8 Mth post dose 3 (N=189;189;194;191)	4	6	7	6

No statistical analyses for this end point

Secondary: Number of subjects with Group A Streptococcus in the nasopharynx – For Cohort 2/Step 2 subjects receiving the 2+1 Schedule

Top of page

End point title

Number of subjects with Group A Streptococcus in the nasopharynx – For Cohort 2/Step 2 subjects receiving the 2+1 Schedule ^[68]

End point description

End point type

Secondary

End point timeframe

At 1 and 5 months (Mth) post-Dose 2, and at 3 months post-Dose 3 of the pneumococcal vaccine administered (10PP vaccine or Synflorix™)

Notes
[68] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Cohort 1 subjects participated in Step 1 . Cohort 2 subjects participated in Step 2. Please, refer to the title of the endpoint: Statistics are presented only for the groups belonging to the concerned Cohort/Step and the vaccination schedule.

End point values	10PP-HD 2+1d Group	Synflorix 2+1d Group
Number of subjects analysed	197	197
Units: Subjects
At 1 Mth post-dose 2 N=(197;197)	6	4
At 5 Mth post-dose 2 N=(189;194)	2	4
At 3 Mths post-dose 3 N=(190;193)	5	2

No statistical analyses for this end point

Secondary: Number of subjects with Staphylococcus aureus in the nasopharynx – For Cohort 2/Step 2 subjects receiving the 3+0 Schedule

Top of page

End point title

Number of subjects with Staphylococcus aureus in the nasopharynx – For Cohort 2/Step 2 subjects receiving the 3+0 Schedule ^[69]

End point description

Positive cultures of other bacterial pathogens [such as S. aureus, Streptococcus pyogenes (Group A streptococci) and Moraxella catarrhalis] identified in the nasopharynx were analyzed.This outcome concerns subjects enrolled in Cohort 2/Step 2 receiving the 3+0 Schedule.

End point type

Secondary

End point timeframe

At 1, 5 and 8 months (Mth) post-Dose 3 of pneumococcal vaccine administered (10PP vaccine, Synflorix™ or Prevnar 13™)

Notes
[69] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Cohort 1 subjects participated in Step 1 . Cohort 2 subjects participated in Step 2. Please, refer to the title of the endpoint: Statistics are presented only for the groups belonging to the concerned Cohort/Step and the vaccination schedule.

End point values	10PP-LD 3+0d Group	10PP-HD 3+0d Group	Synflorix 3+0d Group	Prevnar13 3+0d Group
Number of subjects analysed	193	194	196	196
Units: Subjects
At 1 Mth post dose 3 (N=193;194;196;196)	44	44	54	50
At 5 Mth post dose 3 (N=193;192;194;193)	36	37	39	37
At 8 Mth post dose 3 (N=189;189;194;191)	13	17	25	11

No statistical analyses for this end point

Secondary: Number of subjects with Staphylococcus aureus in the nasopharynx – For Cohort 2/Step 2 subjects receiving the 2+1 Schedule

Top of page

End point title

Number of subjects with Staphylococcus aureus in the nasopharynx – For Cohort 2/Step 2 subjects receiving the 2+1 Schedule ^[70]

End point description

End point type

Secondary

End point timeframe

At 1 and 5 months (Mth) post-Dose 2, and at 3 months post-Dose 3 of the pneumococcal vaccine administered (10PP vaccine or Synflorix™)

Notes
[70] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Cohort 1 subjects participated in Step 1 . Cohort 2 subjects participated in Step 2. Please, refer to the title of the endpoint: Statistics are presented only for the groups belonging to the concerned Cohort/Step and the vaccination schedule.

End point values	10PP-HD 2+1d Group	Synflorix 2+1d Group
Number of subjects analysed	197	197
Units: Subjects
At 1 Mth post-dose 2 N=(197;197)	46	62
At 5 Mth post-dose 2 N=(189;194)	32	40
At 3 Mths post-dose 3 N=(190;193)	21	17

No statistical analyses for this end point

Secondary: Number of subjects with acquisition of non-vaccine serotypes/serogroups of Streptococcus pneumoniae in the nasopharynx – For Cohort 2/Step 2 subjects receiving the 3+0 Schedule

Top of page

End point title

Number of subjects with acquisition of non-vaccine serotypes/serogroups of Streptococcus pneumoniae in the nasopharynx – For Cohort 2/Step 2 subjects receiving the 3+0 Schedule ^[71]

End point description

This outcome concerns subjects enrolled in Cohort 2/Step 2 receiving the 3+0 Schedule.

End point type

Secondary

End point timeframe

At 1, 5 and 8 months (Mth) post-Dose 3 of pneumococcal vaccine administered (10PP vaccine or Synflorix™)

Notes
[71] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Cohort 1 subjects participated in Step 1 . Cohort 2 subjects participated in Step 2. Please, refer to the title of the endpoint: Statistics are presented only for the groups belonging to the concerned Cohort/Step and the vaccination schedule.

End point values	10PP-LD 3+0d Group	10PP-HD 3+0d Group	Synflorix 3+0d Group
Number of subjects analysed	193	194	196
Units: Subjects
At 1 Mth post dose 3 (N=193;194;196)	124	106	120
At 5 Mth post dose 3 (N=192;191;194)	108	122	131
At 8 Mth post dose 3 (N=189;189;193)	121	115	122

No statistical analyses for this end point

Secondary: Number of subjects with acquisition of non-vaccine serotypes/serogroups of Streptococcus pneumoniae in the nasopharynx – For Cohort 2/Step 2 subjects receiving the 2+1 Schedule

Top of page

End point title

Number of subjects with acquisition of non-vaccine serotypes/serogroups of Streptococcus pneumoniae in the nasopharynx – For Cohort 2/Step 2 subjects receiving the 2+1 Schedule ^[72]

End point description

This outcome concerns subjects enrolled in Cohort 2/Step 2 receiving the 2+1 Schedule.

End point type

Secondary

End point timeframe

At 1 and 5 months (Mth) post-Dose 2, and at 3 months post-Dose 3 of the pneumococcal vaccine administered (10PP vaccine or Synflorix™)

Notes
[72] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Cohort 1 subjects participated in Step 1 . Cohort 2 subjects participated in Step 2. Please, refer to the title of the endpoint: Statistics are presented only for the groups belonging to the concerned Cohort/Step and the vaccination schedule.

End point values	10PP-HD 2+1d Group	Synflorix 2+1d Group
Number of subjects analysed	197	197
Units: Subjects
At 1 Mth post-dose 2 N=(197;197)	117	128
At 5 Mth post-dose 2 N=(189;193)	119	138
At 3 Mths post-dose 3 N=(188;192)	129	117

No statistical analyses for this end point

Secondary: Number of subjects with acquisition of any new Streptococcus pneumoniae in the nasopharynx – For Cohort 2/Step 2 subjects receiving the 3+0 Schedule

Top of page

End point title

Number of subjects with acquisition of any new Streptococcus pneumoniae in the nasopharynx – For Cohort 2/Step 2 subjects receiving the 3+0 Schedule ^[73]

End point description

This outcome concerns subjects enrolled in Cohort 2/Step 2 receiving the 3+0 Schedule.

End point type

Secondary

End point timeframe

At 1, 5 and 8 months (Mth) post-Dose 3 of pneumococcal vaccine administered (10PP vaccine or Synflorix™)

Notes
[73] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Cohort 1 subjects participated in Step 1 . Cohort 2 subjects participated in Step 2. Please, refer to the title of the endpoint: Statistics are presented only for the groups belonging to the concerned Cohort/Step and the vaccination schedule.

End point values	10PP-LD 3+0d Group	10PP-HD 3+0d Group	Synflorix 3+0d Group
Number of subjects analysed	193	194	196
Units: Subjects
At 1 Mth post dose 3 (N=193;194;196)	136	130	142
At 5 Mth post dose 3 (N=192;191;194)	128	130	145
At 8 Mth post dose 3 (N=189;189;193)	139	128	136

No statistical analyses for this end point

Secondary: Number of subjects with acquisition of any new Streptococcus pneumoniae in the nasopharynx – For Cohort 2/Step 2 subjects receiving the 2+1 Schedule

Top of page

End point title

Number of subjects with acquisition of any new Streptococcus pneumoniae in the nasopharynx – For Cohort 2/Step 2 subjects receiving the 2+1 Schedule ^[74]

End point description

This outcome concerns subjects enrolled in Cohort 2/Step 2 receiving the 2+1 Schedule.

End point type

Secondary

End point timeframe

At 1 and 5 months (Mth) post-Dose 2, and at 3 months post-Dose 3 of the pneumococcal vaccine administered (10PP vaccine or Synflorix™)

Notes
[74] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Cohort 1 subjects participated in Step 1 . Cohort 2 subjects participated in Step 2. Please, refer to the title of the endpoint: Statistics are presented only for the groups belonging to the concerned Cohort/Step and the vaccination schedule.

End point values	10PP-HD 2+1d Group	Synflorix 2+1d Group
Number of subjects analysed	197	197
Units: Subjects
At 1 Mth post-dose 2 N=(197;197)	136	141
At 5 Mth post-dose 2 N=(189;193)	136	155
At 3 Mths post-dose 3 N=(188;192)	144	131

No statistical analyses for this end point

Adverse events

Top of page

Timeframe for reporting adverse events

Solicited symptoms during the 4-day post-vaccination period in Cohort 1 and 2. Unsolicited AEs during 31-day post-vaccination period in Cohort 1 and 2. SAEs from Month 0 to Month 6 in Cohort 1 and from Month 0 to Month 10 in Cohort 2.

Adverse event reporting additional description

The occurrence of reported AEs (all/related) was not available and is encoded as equal to the number of subjects affected.

Assessment type

Systematic

Dictionary name

MedDRA

Dictionary version

18.1

Reporting group title

10PP-HD 3+0d Group

Reporting group description

This group consisted in infants aged 8-10 weeks at first vaccination enrolled as part the Cohort 2/Step 2 of the study who received 3 doses of the GSK 2189242A (or 10PP) vaccine in its high-dose (HD) formulation and EPI vaccines according to a 3+0 Schedule. That is, subjects received 3 doses of the 10PP vaccine, HD formulation, co-administered with the Tritanrix™-HepB/Hib and Polio Sabin™ at 2-3-4 months of age (Day 0, Month 1 and Month 2), followed by one dose of each of the M-Vac™, Stamaril™ and Polio Sabin™ vaccines administered at approximately 9 months of age. The 10PP vaccine was administered intramuscularly into the right thigh; Tritanrix™-HepB/Hib, M-Vac™ and Stamaril™ were administered intramuscularly into the left thigh; Polio Sabin™ was administered orally.

Reporting group title

Synflorix 3+0d Group

Reporting group description

Reporting group title

Prevnar 13 3+0d Group

Reporting group description

Reporting group title

10PP-HD 2+1d Group

Reporting group description

Reporting group title

Synflorix 2+1d Group

Reporting group description

Reporting group title

10PP-HD 1d Group

Reporting group description

Group This group consisted in children aged 2-4 years at vaccination enrolled as part of the Cohort 1/Step 1 of the study who received a single dose of the GSK 2189242A (or 10PP) vaccine in its high-dose (HD) formulation at Day 0. The 10PP vaccine was administered intramuscularly in the non-dominant deltoid.

Reporting group title

Prevnar 13 1d Group

Reporting group description

Reporting group title

10PP-LD 3+0d Group

Reporting group description

Serious adverse events	10PP-HD 3+0d Group	Synflorix 3+0d Group	Prevnar 13 3+0d Group	10PP-HD 2+1d Group	Synflorix 2+1d Group	10PP-HD 1d Group	Prevnar 13 1d Group	10PP-LD 3+0d Group
Total subjects affected by serious adverse events
subjects affected / exposed	4 / 200 (2.00%)	3 / 200 (1.50%)	2 / 200 (1.00%)	4 / 200 (2.00%)	5 / 200 (2.50%)	0 / 60 (0.00%)	0 / 60 (0.00%)	1 / 200 (0.50%)
number of deaths (all causes)	1	0	2	2	1	0	0	0
number of deaths resulting from adverse events
Nervous system disorders
Febrile convulsion
subjects affected / exposed	0 / 200 (0.00%)	0 / 200 (0.00%)	0 / 200 (0.00%)	0 / 200 (0.00%)	1 / 200 (0.50%)	0 / 60 (0.00%)	0 / 60 (0.00%)	0 / 200 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0	0 / 0	0 / 1	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions
Sudden infant death syndrome
subjects affected / exposed	0 / 200 (0.00%)	0 / 200 (0.00%)	0 / 200 (0.00%)	1 / 200 (0.50%)	0 / 200 (0.00%)	0 / 60 (0.00%)	0 / 60 (0.00%)	0 / 200 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0	0 / 1	0 / 0	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0	0 / 1	0 / 0	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders
Pneumonia aspiration
subjects affected / exposed	1 / 200 (0.50%)	0 / 200 (0.00%)	0 / 200 (0.00%)	0 / 200 (0.00%)	0 / 200 (0.00%)	0 / 60 (0.00%)	0 / 60 (0.00%)	0 / 200 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0
Infections and infestations
Pneumonia
subjects affected / exposed	1 / 200 (0.50%)	2 / 200 (1.00%)	1 / 200 (0.50%)	2 / 200 (1.00%)	0 / 200 (0.00%)	0 / 60 (0.00%)	0 / 60 (0.00%)	0 / 200 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 1	0 / 2	0 / 0	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0
Gastroenteritis
subjects affected / exposed	1 / 200 (0.50%)	0 / 200 (0.00%)	0 / 200 (0.00%)	1 / 200 (0.50%)	1 / 200 (0.50%)	0 / 60 (0.00%)	0 / 60 (0.00%)	0 / 200 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0	0 / 1	0 / 1	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0	0 / 1	0 / 1	0 / 0	0 / 0	0 / 0
Sepsis
subjects affected / exposed	0 / 200 (0.00%)	1 / 200 (0.50%)	1 / 200 (0.50%)	0 / 200 (0.00%)	1 / 200 (0.50%)	0 / 60 (0.00%)	0 / 60 (0.00%)	0 / 200 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1	0 / 0	0 / 1	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0
Bronchiolitis
subjects affected / exposed	1 / 200 (0.50%)	0 / 200 (0.00%)	0 / 200 (0.00%)	0 / 200 (0.00%)	1 / 200 (0.50%)	0 / 60 (0.00%)	0 / 60 (0.00%)	0 / 200 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0	0 / 0	0 / 1	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0
Bronchitis
subjects affected / exposed	0 / 200 (0.00%)	0 / 200 (0.00%)	0 / 200 (0.00%)	0 / 200 (0.00%)	1 / 200 (0.50%)	0 / 60 (0.00%)	0 / 60 (0.00%)	0 / 200 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0	0 / 0	0 / 1	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0
Malaria
subjects affected / exposed	0 / 200 (0.00%)	0 / 200 (0.00%)	0 / 200 (0.00%)	0 / 200 (0.00%)	0 / 200 (0.00%)	0 / 60 (0.00%)	0 / 60 (0.00%)	1 / 200 (0.50%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0
Meningitis bacterial
subjects affected / exposed	1 / 200 (0.50%)	0 / 200 (0.00%)	0 / 200 (0.00%)	0 / 200 (0.00%)	0 / 200 (0.00%)	0 / 60 (0.00%)	0 / 60 (0.00%)	0 / 200 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0

Frequency threshold for reporting non-serious adverse events: 5%

Non-serious adverse events	10PP-HD 3+0d Group	Synflorix 3+0d Group	Prevnar 13 3+0d Group	10PP-HD 2+1d Group	Synflorix 2+1d Group	10PP-HD 1d Group	Prevnar 13 1d Group	10PP-LD 3+0d Group
Total subjects affected by non serious adverse events
subjects affected / exposed	195 / 200 (97.50%)	195 / 200 (97.50%)	191 / 200 (95.50%)	184 / 200 (92.00%)	181 / 200 (90.50%)	5 / 60 (8.33%)	2 / 60 (3.33%)	189 / 200 (94.50%)
Nervous system disorders
Somnolence-Cohort2:3+0 schedule
subjects affected / exposed	46 / 200 (23.00%)	38 / 200 (19.00%)	44 / 200 (22.00%)	0 / 200 (0.00%)	0 / 200 (0.00%)	0 / 60 (0.00%)	0 / 60 (0.00%)	43 / 200 (21.50%)
occurrences all number	46	38	44	0	0	0	0	43
Somnolence-Cohort2:2+1 schedule-first 2 doses
subjects affected / exposed	0 / 200 (0.00%)	0 / 200 (0.00%)	0 / 200 (0.00%)	47 / 200 (23.50%)	44 / 200 (22.00%)	0 / 60 (0.00%)	0 / 60 (0.00%)	0 / 200 (0.00%)
occurrences all number	0	0	0	47	44	0	0	0
Somnolence-Cohort2:2+1 schedule-third dose
subjects affected / exposed ^[1]	0 / 200 (0.00%)	0 / 200 (0.00%)	0 / 200 (0.00%)	12 / 191 (6.28%)	4 / 195 (2.05%)	0 / 60 (0.00%)	0 / 60 (0.00%)	0 / 200 (0.00%)
occurrences all number	0	0	0	12	4	0	0	0
General disorders and administration site conditions
Fever (axillary temperature ≥ 37.5°C) (1 dose Group)
subjects affected / exposed	0 / 200 (0.00%)	0 / 200 (0.00%)	0 / 200 (0.00%)	0 / 200 (0.00%)	0 / 200 (0.00%)	4 / 60 (6.67%)	2 / 60 (3.33%)	0 / 200 (0.00%)
occurrences all number	0	0	0	0	0	4	2	0
Pain-Cohort2:3+0 schedule
subjects affected / exposed	121 / 200 (60.50%)	123 / 200 (61.50%)	115 / 200 (57.50%)	0 / 200 (0.00%)	0 / 200 (0.00%)	0 / 60 (0.00%)	0 / 60 (0.00%)	108 / 200 (54.00%)
occurrences all number	121	123	115	0	0	0	0	108
Swelling-Cohort2:3+0 schedule
subjects affected / exposed	45 / 200 (22.50%)	40 / 200 (20.00%)	37 / 200 (18.50%)	0 / 200 (0.00%)	0 / 200 (0.00%)	0 / 60 (0.00%)	0 / 60 (0.00%)	30 / 200 (15.00%)
occurrences all number	45	40	37	0	0	0	0	30
Pain-Cohort2:2+1 schedule-first 2 doses
subjects affected / exposed	0 / 200 (0.00%)	0 / 200 (0.00%)	0 / 200 (0.00%)	97 / 200 (48.50%)	102 / 200 (51.00%)	0 / 60 (0.00%)	0 / 60 (0.00%)	0 / 200 (0.00%)
occurrences all number	0	0	0	97	102	0	0	0
Swelling-Cohort2:2+1 schedule-first 2 doses
subjects affected / exposed	0 / 200 (0.00%)	0 / 200 (0.00%)	0 / 200 (0.00%)	35 / 200 (17.50%)	31 / 200 (15.50%)	0 / 60 (0.00%)	0 / 60 (0.00%)	0 / 200 (0.00%)
occurrences all number	0	0	0	35	31	0	0	0
Pain-Cohort2:2+1 schedule-third dose
subjects affected / exposed ^[2]	0 / 200 (0.00%)	0 / 200 (0.00%)	0 / 200 (0.00%)	21 / 191 (10.99%)	26 / 195 (13.33%)	0 / 60 (0.00%)	0 / 60 (0.00%)	0 / 200 (0.00%)
occurrences all number	0	0	0	21	26	0	0	0
Pyrexia-Cohort 2:3+0 schedule
subjects affected / exposed	104 / 200 (52.00%)	106 / 200 (53.00%)	106 / 200 (53.00%)	0 / 200 (0.00%)	0 / 200 (0.00%)	0 / 60 (0.00%)	0 / 60 (0.00%)	105 / 200 (52.50%)
occurrences all number	104	106	106	0	0	0	0	105
Pyrexia-Cohort2:2+1 schedule-first 2 doses
subjects affected / exposed	0 / 200 (0.00%)	0 / 200 (0.00%)	0 / 200 (0.00%)	93 / 200 (46.50%)	89 / 200 (44.50%)	0 / 60 (0.00%)	0 / 60 (0.00%)	0 / 200 (0.00%)
occurrences all number	0	0	0	93	89	0	0	0
Pyrexia-Cohort2:2+1 schedule-third dose
subjects affected / exposed ^[3]	0 / 200 (0.00%)	0 / 200 (0.00%)	0 / 200 (0.00%)	32 / 191 (16.75%)	27 / 195 (13.85%)	0 / 60 (0.00%)	0 / 60 (0.00%)	0 / 200 (0.00%)
occurrences all number	0	0	0	32	27	0	0	0
Psychiatric disorders
Irritability-Cohort2:3+0 schedule
subjects affected / exposed	133 / 200 (66.50%)	141 / 200 (70.50%)	136 / 200 (68.00%)	0 / 200 (0.00%)	0 / 200 (0.00%)	0 / 60 (0.00%)	0 / 60 (0.00%)	139 / 200 (69.50%)
occurrences all number	133	141	136	0	0	0	0	139
Irritability-Cohort2:2+1 schedule-first 2 doses
subjects affected / exposed	0 / 200 (0.00%)	0 / 200 (0.00%)	0 / 200 (0.00%)	131 / 200 (65.50%)	128 / 200 (64.00%)	0 / 60 (0.00%)	0 / 60 (0.00%)	0 / 200 (0.00%)
occurrences all number	0	0	0	131	128	0	0	0
Irritability-Cohort2:2+1 schedule-third dose
subjects affected / exposed ^[4]	0 / 200 (0.00%)	0 / 200 (0.00%)	0 / 200 (0.00%)	27 / 191 (14.14%)	19 / 195 (9.74%)	0 / 60 (0.00%)	0 / 60 (0.00%)	0 / 200 (0.00%)
occurrences all number	0	0	0	27	19	0	0	0
Infections and infestations
Respiratory tract infection-Cohort 1
subjects affected / exposed	0 / 200 (0.00%)	0 / 200 (0.00%)	0 / 200 (0.00%)	0 / 200 (0.00%)	0 / 200 (0.00%)	5 / 60 (8.33%)	1 / 60 (1.67%)	0 / 200 (0.00%)
occurrences all number	0	0	0	0	0	5	1	0
Respiratory tract infection-Cohort2:3+0 schedule
subjects affected / exposed	68 / 200 (34.00%)	80 / 200 (40.00%)	80 / 200 (40.00%)	0 / 200 (0.00%)	0 / 200 (0.00%)	0 / 60 (0.00%)	0 / 60 (0.00%)	80 / 200 (40.00%)
occurrences all number	68	80	80	0	0	0	0	80
Upper respiratory tract infection-Cohort2:3+0 schedule
subjects affected / exposed	14 / 200 (7.00%)	12 / 200 (6.00%)	10 / 200 (5.00%)	0 / 200 (0.00%)	0 / 200 (0.00%)	0 / 60 (0.00%)	0 / 60 (0.00%)	12 / 200 (6.00%)
occurrences all number	14	12	10	0	0	0	0	12
Respiratory tract infection-Cohort2:2+1 schedule-first 2 doses
subjects affected / exposed	0 / 200 (0.00%)	0 / 200 (0.00%)	0 / 200 (0.00%)	56 / 200 (28.00%)	58 / 200 (29.00%)	0 / 60 (0.00%)	0 / 60 (0.00%)	0 / 200 (0.00%)
occurrences all number	0	0	0	56	58	0	0	0
Conjunctivitis-Cohort2:3+0 schedule
subjects affected / exposed	4 / 200 (2.00%)	10 / 200 (5.00%)	6 / 200 (3.00%)	0 / 200 (0.00%)	0 / 200 (0.00%)	0 / 60 (0.00%)	0 / 60 (0.00%)	6 / 200 (3.00%)
occurrences all number	4	10	6	0	0	0	0	6
Metabolism and nutrition disorders
Decreased appetite-Cohort2:3+0 schedule
subjects affected / exposed	30 / 200 (15.00%)	27 / 200 (13.50%)	34 / 200 (17.00%)	0 / 200 (0.00%)	0 / 200 (0.00%)	0 / 60 (0.00%)	0 / 60 (0.00%)	32 / 200 (16.00%)
occurrences all number	30	27	34	0	0	0	0	32
Decreased appetite-Cohort2:2+1 schedule-first 2 doses
subjects affected / exposed	0 / 200 (0.00%)	0 / 200 (0.00%)	0 / 200 (0.00%)	24 / 200 (12.00%)	25 / 200 (12.50%)	0 / 60 (0.00%)	0 / 60 (0.00%)	0 / 200 (0.00%)
occurrences all number	0	0	0	24	25	0	0	0

Notes
[1] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.
Justification: The analysis of the solicited symptom included only subjects with documented data.
[2] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.
Justification: The analysis of the solicited symptom included only subjects with documented data.
[3] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.
Justification: The analysis of the solicited symptom included only subjects with documented data.
[4] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.
Justification: The analysis of the solicited symptom included only subjects with documented data.

More information

Top of page

Were there any global substantial amendments to the protocol? Yes

04 Oct 2010

- Following comments from Scientific Committee in the Gambia the inclusion/exclusion criteria were modified as follows: The criterion of gestational age has been removed from the inclusion criteria as the exact duration of pregnancy is difficult to retrieve in this population; Reference to HIV infection has been removed from the exclusion criteria. - In addition follow-up period of solicited adverse events has been shortened from 7 days (Day 0 - Day 6) to 4 days (Day 0 - Day 3) following vaccination in order to adjust to the scheduled field workers’ visits and due to the difficulty to collect information in this population retrospectively for day 4 and day 5, when no field worker visit is performed. Consequently, field worker visits at day 6 have been removed.

10 Mar 2011

- Following advice from IDMC, the following change has been implemented: Safety analysis that will lead to a decision to begin enrolment in Cohort 2 will be done on all enrolled children from cohort 1 (approximately 120 subjects) instead of the first 60 enrolled subjects. In addition, the following changes have been included: - OPA assay testing techniques have been broadened by inclusion of OPA multiplex to OPA standard testing. Multiplex assay will be used in this study and future studies as it allows multiple measurements in one single test, so it would result in reduction in sera volume needed for OPA in future studies. Likewise, a multiplex immunochemistry assay with equivalent characteristics to the 22Finhibition ELISA assay and bridged to the 22F-inhibition ELISA might be used in this study. - As a result of assay qualification, the cut-off for the functional assay measuring the inhibition of pneumolysin haemolysis activity was changed to 140 instead of 6. Quantitative serotype-specific PCR was added to the list of bacterial diagnosis testing on the nasopharyngeal swabs that may be done if specific validated assays become available in the GSK Biologicals laboratory or a validated laboratory designated by GSK Biologicals or deemed necessary should the results of this study and/or another study require it or for development of new assays regarding the diseases or vaccines under evaluation.

06 Oct 2011

- In order to comply with the national immunisation program, a dose of OPV was to be administered to subjects from Cohort 2, at the time of Visit 5 (at approximately 9 months of age). - Vaccines such as Polio, Measles or Meningococcal Vaccines that are recommended as part of national campaigns for immunisation were now allowed to be administered at any time during the study. - Complementary analysis of immunogenicity of co-administered vaccines depending on number of received doses has been envisaged. - In the microbiological assessment section the possibility to perform additional testing on the nasopharyngeal swabs for viral pathogens has been added. - Some inconsistencies in protocol wording that could lead to misinterpretation have been clarified throughout the document.

19 Jun 2012

- At the European Medicines Agency’s (EMA) request, GSK Biologicals has updated its procedure for emergency unblinding during the conduct of a clinical study. - According to the revised procedure, the responsibility and the decision to break the treatment code in emergency situations resides solely with the investigator and consequently, the investigator will have full authority to break the treatment code. - The anti-PD, anti-Ply, anti-PhtD Luminex assay has been initially developed and qualified using sera samples from subjects having natural immunity against these 3 proteins. The assay has been evaluated in phase I - II studies and in SPNG005 Cohort 1. During re-qualification with standard based on post- vaccination serum, assay consistency was found to be insufficient. Therefore, the Luminex 3-plex anti-PD, -Ply, -PhtD was replaced by 3 qualified individual ELISAs.

Were there any global interruptions to the trial? No

Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.

Anti-Ply haemolysis activity inhibition assay for cohort 2 analysis was no longer available.No analysis was performed for acquisition of new H. influenzae in nasopharynx and for ELISA and OPA-6C as no specific qualified/validated assay was available.

Select Country:	Select Age Range:
Select Trial Status:	Select Trial Phase:
Select Gender:
Select Date Range: to
Select Rare Disease:
IMP with orphan designation in the indication
Orphan Designation Number:
Results Status:
Clear advanced search filters

Austria
Belgium
Bulgaria
Croatia
Cyprus
Czechia
Denmark
Estonia
Finland
France
Germany
Greece
Hungary
Iceland
Ireland
Italy
Latvia
Liechtenstein
Lithuania
Luxembourg
Malta
Netherlands
Norway
Poland
Portugal
Romania
Slovakia
Slovenia
Spain
Sweden
United Kingdom
Outside EU/EEA

Clinical trials

Trial information

Trial information

Subject disposition

Subject disposition

Baseline characteristics

Baseline characteristics

End points

End points

Primary: Number of subjects with any and Grade 3 solicited local symptoms and Grade 3 solicited local symptoms with relationship to vaccination – For Step 1/Cohort 1 subjects

Primary: Number of subjects with any and Grade 3 solicited local symptoms and Grade 3 solicited local symptoms with relationship to vaccination – For Step 1/Cohort 1 subjects

Primary: Number of subjects with any and Grade 3 solicited general symptoms with and without relationship to vaccination – For Step 1/Cohort 1 subjects

Primary: Number of subjects with any and Grade 3 solicited general symptoms with and without relationship to vaccination – For Step 1/Cohort 1 subjects

Primary: Number of subjects with any and Grade 3 unsolicited adverse events (AEs) with and without relationship to vaccination - For Step 1/Cohort 1 subjects

Primary: Number of subjects with any and Grade 3 unsolicited adverse events (AEs) with and without relationship to vaccination - For Step 1/Cohort 1 subjects

Primary: Number of subjects with any serious adverse events (SAEs) and with SAE(s) with relationship to vaccination - For Step 1/Cohort 1 subjects

Primary: Number of subjects with any serious adverse events (SAEs) and with SAE(s) with relationship to vaccination - For Step 1/Cohort 1 subjects

Primary: Number of subjects with non-vaccine serotypes of Streptococcus pneumoniae (S. pn.) in the nasopharynx – For Cohort 2/Step 2, subjects receiving the 3+0 Schedule

Primary: Number of subjects with non-vaccine serotypes of Streptococcus pneumoniae (S. pn.) in the nasopharynx – For Cohort 2/Step 2, subjects receiving the 3+0 Schedule

Primary: Number of subjects with non-vaccine serotypes of Streptococcus pneumoniae (S. pn.) in the nasopharynx – For Cohort 2/Step 2, subjects receiving the 2+1 Schedule

Primary: Number of subjects with non-vaccine serotypes of Streptococcus pneumoniae (S. pn.) in the nasopharynx – For Cohort 2/Step 2, subjects receiving the 2+1 Schedule

Secondary: Number of subjects with haematological or biochemical abnormalities with respect to normal laboratory ranges – For Cohort 1/Step 1 subjects

Secondary: Number of subjects with haematological or biochemical abnormalities with respect to normal laboratory ranges – For Cohort 1/Step 1 subjects

Secondary: Number of subjects with serious adverse events (SAEs) – For Step 1/Cohort 1 subjects

Secondary: Number of subjects with serious adverse events (SAEs) – For Step 1/Cohort 1 subjects

Secondary: Antibody concentrations against pneumococcal pneumolysin toxoid (Ply) and pneumococcal histidine triad protein D (PhtD) proteins – For Cohort 1/Step 1 subjects

Secondary: Antibody concentrations against pneumococcal pneumolysin toxoid (Ply) and pneumococcal histidine triad protein D (PhtD) proteins – For Cohort 1/Step 1 subjects

Secondary: Antibody concentrations against Protein D (PD) – For Cohort 1/Step 1 subjects

Secondary: Antibody concentrations against Protein D (PD) – For Cohort 1/Step 1 subjects

Secondary: Antibody concentrations against vaccine serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F – For Cohort 1/Step 1 subjects

Secondary: Antibody concentrations against vaccine serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F – For Cohort 1/Step 1 subjects

Secondary: Antibody concentrations against vaccine serotypes 3, 6A and 19A – For Cohort 1/Step 1 subjects

Secondary: Antibody concentrations against vaccine serotypes 3, 6A and 19A – For Cohort 1/Step 1 subjects

Secondary: Titers for opsonophagocytic activity against vaccine serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F – For Cohort 1/Step 1 subjects

Secondary: Titers for opsonophagocytic activity against vaccine serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F – For Cohort 1/Step 1 subjects

Secondary: Titers for opsonophagocytic activity against vaccine serotypes 3, 6A and 19A – For Cohort 1/Step 1 subjects

Secondary: Titers for opsonophagocytic activity against vaccine serotypes 3, 6A and 19A – For Cohort 1/Step 1 subjects

Secondary: Concentrations of antibodies inhibiting pneumococcal pneumolysin toxoid (Ply) haemolysis activity, or Hem-Ply antibodies – For Cohort 1/Step 1 subjects

Secondary: Concentrations of antibodies inhibiting pneumococcal pneumolysin toxoid (Ply) haemolysis activity, or Hem-Ply antibodies – For Cohort 1/Step 1 subjects

Secondary: Number of subjects with any and Grade 3 solicited local symptoms – For Cohort2/Step 2 subjects receiving the 3+0 Schedule

Secondary: Number of subjects with any and Grade 3 solicited local symptoms – For Cohort2/Step 2 subjects receiving the 3+0 Schedule

Secondary: Number of subjects with any and Grade 3 solicited local symptoms – For Cohort2/Step 2 subjects receiving the 2+1 Schedule

Secondary: Number of subjects with any and Grade 3 solicited local symptoms – For Cohort2/Step 2 subjects receiving the 2+1 Schedule

Secondary: Number of subjects with any and Grade 3 solicited local symptoms – For Cohort2/Step 2 subjects receiving the 2+1 Schedule

Secondary: Number of subjects with any and Grade 3 solicited local symptoms – For Cohort2/Step 2 subjects receiving the 2+1 Schedule

Secondary: Number of subjects with any and Grade 3 solicited general symptoms and with solicited general symptoms with relationship to vaccination – For Step 2/Cohort 2 subjects receiving the 3+0 Schedule

Secondary: Number of subjects with any and Grade 3 solicited general symptoms and with solicited general symptoms with relationship to vaccination – For Step 2/Cohort 2 subjects receiving the 3+0 Schedule

Secondary: Number of subjects with any and Grade 3 solicited general symptoms and with solicited general symptoms with relationship to vaccination – For Step 2/Cohort 2 subjects receiving the 2+1 Schedule

Secondary: Number of subjects with any and Grade 3 solicited general symptoms and with solicited general symptoms with relationship to vaccination – For Step 2/Cohort 2 subjects receiving the 2+1 Schedule

Secondary: Number of subjects with any and Grade 3 solicited general symptoms and with solicited general symptoms with relationship to vaccination – For Step 2/Cohort 2 subjects receiving the 2+1 Schedule

Secondary: Number of subjects with any and Grade 3 solicited general symptoms and with solicited general symptoms with relationship to vaccination – For Step 2/Cohort 2 subjects receiving the 2+1 Schedule

Secondary: Number of subjects with any unsolicited adverse events (AEs) – For Step 2/Cohort 2 subjects receiving the 3+0 Schedule

Secondary: Number of subjects with any unsolicited adverse events (AEs) – For Step 2/Cohort 2 subjects receiving the 3+0 Schedule

Secondary: Number of subjects with any unsolicited adverse events (AEs) – For Step 2/Cohort 2 subjects receiving the 2+1 Schedule

Secondary: Number of subjects with any unsolicited adverse events (AEs) – For Step 2/Cohort 2 subjects receiving the 2+1 Schedule

Secondary: Antibody concentrations against pneumococcal pneumolysin toxoid (Ply) and pneumococcal histidine triad protein D (PhtD) proteins – For Cohort 2/Step 2 subjects receiving the 3+0 Schedule

Secondary: Antibody concentrations against pneumococcal pneumolysin toxoid (Ply) and pneumococcal histidine triad protein D (PhtD) proteins – For Cohort 2/Step 2 subjects receiving the 3+0 Schedule

Secondary: Antibody concentrations against pneumococcal pneumolysin toxoid (Ply) and pneumococcal histidine triad protein D (PhtD) proteins – For Cohort 2/Step 2 subjects receiving the 2+1 Schedule

Secondary: Antibody concentrations against pneumococcal pneumolysin toxoid (Ply) and pneumococcal histidine triad protein D (PhtD) proteins – For Cohort 2/Step 2 subjects receiving the 2+1 Schedule

Secondary: Antibody concentrations against Protein D (PD) – For Cohort 2/Step 2 subjects receiving the 3+0 Schedule

Secondary: Antibody concentrations against Protein D (PD) – For Cohort 2/Step 2 subjects receiving the 3+0 Schedule

Secondary: Antibody concentrations against Protein D (PD) – For Cohort 2/Step 2 subjects receiving the 2+1 Schedule

Secondary: Antibody concentrations against Protein D (PD) – For Cohort 2/Step 2 subjects receiving the 2+1 Schedule

Secondary: Antibody concentrations against vaccine serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F – For Cohort 2/Step 2 subjects who received the 3+0 Schedule

Secondary: Antibody concentrations against vaccine serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F – For Cohort 2/Step 2 subjects who received the 3+0 Schedule

Secondary: Antibody concentrations against vaccine serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F – For Cohort 2/Step 2 subjects who received the 2+1 Schedule

Secondary: Antibody concentrations against vaccine serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F – For Cohort 2/Step 2 subjects who received the 2+1 Schedule

Secondary: Antibody concentrations against vaccine serotypes 3, 6A and 19A – For Cohort 2/Step 2 subjects who received the 3+0 Schedule

Secondary: Antibody concentrations against vaccine serotypes 3, 6A and 19A – For Cohort 2/Step 2 subjects who received the 3+0 Schedule

Secondary: Antibody concentrations against vaccine serotypes 3, 6A and 19A – For Cohort 2/Step 2 subjects who received the 2+1 Schedule

Secondary: Antibody concentrations against vaccine serotypes 3, 6A and 19A – For Cohort 2/Step 2 subjects who received the 2+1 Schedule

Secondary: Titers for opsonophagocytic activity against vaccine serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F – For Cohort 2/Step 2 subjects receiving the 3+0 Schedule

Secondary: Titers for opsonophagocytic activity against vaccine serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F – For Cohort 2/Step 2 subjects receiving the 3+0 Schedule

Secondary: Titers for opsonophagocytic activity against vaccine serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F – For Cohort 2/Step 2 subjects receiving the 2+1 Schedule

Secondary: Titers for opsonophagocytic activity against vaccine serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F – For Cohort 2/Step 2 subjects receiving the 2+1 Schedule

Secondary: Titers for opsonophagocytic activity against vaccine serotypes 3, 6A and 19A – For Cohort 2/Step 2 subjects receiving the 3+0 Schedule

Secondary: Titers for opsonophagocytic activity against vaccine serotypes 3, 6A and 19A – For Cohort 2/Step 2 subjects receiving the 3+0 Schedule

Secondary: Titers for opsonophagocytic activity against vaccine serotypes 3, 6A and 19A – For Cohort 2/Step 2 subjects receiving the 2+1 Schedule

Secondary: Titers for opsonophagocytic activity against vaccine serotypes 3, 6A and 19A – For Cohort 2/Step 2 subjects receiving the 2+1 Schedule

Secondary: Concentrations of antibodies against diphteria (Anti-D) and tetanus (Anti-T) – For Cohort 2/Step 2 subjects receiving the 3+0 Schedule